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ABSTRACT
EFFECTS OF ZOLEDRONATE DURING SIMULATED WEIGHTLESSNESS ON
BONE STRUCTURE AND MECHANICS
by Ryan T. Scott
Spaceflight causes astronauts to experience an unbalanced level of bone
remodeling favoring resorption. The combination of an antiresorptive drug and
weightlessness may have negative effects on the mechanical and structural
properties of bone by increasing elastic stiffness but diminishing plasticity. At 16
weeks of age, skeletally postpubescent male mice (n = 32, C57BL/6) were evenly
divided and subcutaneously given either zoledronate (45 µg/kg) or vehicle
(saline, same volume). Three days postinjection, half of each group were divided
to undergo 3 weeks of hindlimb unloading or act as a control undergoing normal
ambulation (n = 8 for each of the 4 groups). Ex vivo µCT assays showed
zoledronate preserving cancellous mineral, bone, and cortical bone. Hindlimb
unloading reduced cortical bone. Three-point bending of the femoral mid-shaft
showed zoledronate increased stiffness, ultimate force, and total energy (+28%,
+17%, +15%, respectively). Hindlimb unloading reduced stiffness but increased
postyield displacement, a measurement of plasticity (-29%, +20%, respectively).
The combined treatment resulted in increased stiffness, with zoledronate not
modulating the hindlimb unloading main effect on postyield displacement.
Though stiffness increased, contrary to the hypothesis, the combination of
zoledronate and hindlimb unloading did not result in a decreased plasticity.
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Chapter I
Introduction
Problem
A central challenge in conducting human spaceflight missions is the
maintenance of bone health. More basic scientific research is needed to
elucidate the deleterious effects of microgravity on animal and human bones. In
the coming decades, missions will be scheduled to advance humanity into a new
frontier of exploration past the Van Allen belts, toward Mars, establishing lunar
bases, or toward Lagrange points. A better understanding of bone
mechanobiology will be needed to facilitate the development of effective
countermeasures and mitigation regimens to enable long-term human
spaceflight.
Frost (2003) is credited with first describing the skeletal system’s
biological interaction with its environment being akin to a “mechanostat,” with the
bone structure adapting to the specific imposed environmental demands. This
bone remodeling is accomplished through both bone formation and resorption.
Other factors in this mechanostat theory include bone geometry, metabolic
status, genotype, tissue interaction, and local tissue response (Beaupre, Orr, &
Carter, 1990). Osteoclasts are the cells of the bone responsible for resorption,
osteoblasts are responsible for bone formation, and osteocytes are thought to
coordinate the response to mechanical and metabolic signals (Crockett, Rogers,
Coxon, Hocking & Helfrich, 2011).
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Adverse spaceflight-related bone alterations are partly due to prolonged
periods of weightless unloading referred to as microgravity. This arises from a
lack of muscular and gravitational forces upon bone as would be experienced on
Earth. The lack of weight experienced by astronauts assigned to the
International Space Station (ISS) is from free fall. The vacuum of space (outside
of Earth’s atmosphere) and the gravity of Earth both factor into objects falling
toward Earth at the same rate, irrespective of an object’s mass (Turner, 2000).
This unloading effect from microgravity on the musculoskeletal system negatively
alters bone structure, reduces the collagen matrix mineralization, impacts
osteocellular activity, decreases the amount of bone, and impairs mechanical
properties (Keyak, Koyama, LeBlanc, Lu, & Lang, 2009; Smith et al., 2014). This
can lead to increased probability of fracture. For astronauts who are tasked with
physically strenuous work such as extravehicular activities, this could lead to
devastating consequences during spaceflight missions (Orwoll et al., 2013).
During 6-month ISS missions, bone remodeling favors resorption by
osteoclasts (Smith, Wastney, et al., 2005). This increase in bone resorption is
notable, with bone formation undergoing little change compared to ground
controls (Calliot-Augusseau et al., 1998; Smith, Zwart, Block, Rice, & DavisStreet, 2005). Astronauts present with a rate of bone loss about 10 times greater
than the rate of bone loss by postmenopausal women on earth (Smith et al.,
2014).
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Microgravity-induced bone loss occurs preferentially at the site of weightbearing bones, with an early and pronounced loss of cancellous bone (Collet et
al., 1997; Lang et al., 2004; LeBlanc et al., 2000; Vico et al., 2000). Vico and
colleagues (2000) investigated astronauts who served on 2-month and 6-month
missions. The loss of vertebral bone mineral density (BMD) was 0.9% per
month, and hip BMD losses were 1.4% per month. Through the application of
computed tomography scanning and finite element modeling techniques, the loss
of bone strength in the femur of astronauts has been shown to be much greater
than the changes in BMD (Keyak et al., 2009).
With the recent ISS utilization of the Advanced Resistive Exercise Device
(ARED), crews have had access to high-force resistance training protocols. The
ARED is able to generate absolute loads up to 272 kg (600 lbs) of force (Loehr et
al., 2010). This has resulted in bone formation increases during flight (Smith et
al., 2014). While the inclusion of ARED was the first successful countermeasure
for astronaut bone loss by increasing bone formation, this has not necessarily
solved the challenge of heightened bone resorption. Spaceflight ARED heavy
resistance training did not inhibit the increases of osteoclast activity and bone
resorption. Both bone resorption and bone formation indices from blood and
urinary markers have been shown to stay above prelaunch baselines during
missions with astronauts using ARED (Smith et al., 2012). The increase in the
skeletal remodeling rate is referred to as high bone turnover, with increases in
both osteoblast bone formation and osteoclast bone resorption. Chronic high
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bone turnover experienced by astronauts during long duration spaceflight raises
potential concerns of negative structural and mechanical side effects on bone
health, such as atypical femoral fractures and stress fractures. Additional
countermeasures to specifically inhibit bone resorption have been researched
and considered for astronauts during extended space missions (LeBlanc et al.,
2013).
Zoledronate, a member of the bisphosphonate class of drugs, has been
proposed for long-term spaceflight missions as an antiresorptive countermeasure
targeting osteoclasts. It can prevent weightlessness-induced bone loss in a
hindlimb unloading rodent model, and it is currently prescribed by physicians as
an effective agent for the management of osteoporosis (Lloyd, Travis, Lu, &
Bateman, 2008; Reid et al., 2002).
Medicinal chemists specifically developed zoledronate, which contains a
nitrogen atom within heterocyclic rings at the R2 side chain of the carbon atom of
the phosphate-carbon-phosphate (P-C-P) backbone common among all
bisphosphonates (Kavanagh et al., 2006; Russell, 2011). Zoledronate is the
most potent antiresorptive drug, having the highest mineral binding affinity
(Ebetino et al., 2011). With bisphosphonates inhibiting osteoclasts and bone
resorption, the amount of hydroxyapatite (HAP) mineral increases due to
unhindered osteoblast bone formation activity. The result is a greater amount of
mineral per bone volume (Allen & Burr, 2007; Boivin, Chavassieux, Santora,
Yates, & Meunier, 2000; Burr et al., 2003). Whole-bone mechanical properties of
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stiffness and strength (ultimate force) increase with bisphosphonate treatments
(Allen & Burr, 2007, 2011). Mineral HAP is considerably stiffer than the bone
collagen molecules to which it is bound (Fratzl & Weinkamer, 2007).
Several factors affect the pharmacological impact and lasting potency of
bisphosphonates. Once delivered through the bloodstream, the bisphosphonate
compounds specifically target and bind to bone according to the drug’s mineral
binding affinity. Osteoclasts migrate and undergo a process of polarization,
vesicular trafficking, mineral dissolution, and ultimately bone resorption. The
bisphosphonate previously bound to the bony matrix is released as bone is
resorbed and taken up into the cell (Coxon & Taylor, 2008).
Once taken up by the osteoclast, bisphosphonates inhibit bone resorption
through intracellular effects. When a nitrogen-containing bisphosphonate is
incorporated into the osteoclast cell, it has been shown to interrupt a prominent
target enzyme in the mevalonate biosynthetic pathway: farnesyl pyrophosphate
synthase (FPPS) (Amin et al., 1992). The interruption of this pathway leads to
substrate depletion of farnesyl pyrophosphate (FPP) and geranylgeranyl
pyrophospate (GGPP) lipid groups (Rogers et al., 2000). Small GTPase proteins
including Rac, Rho, and Rabs each rely on posttranslational covalent addition
(prenylation) of these lipid substrates onto their respective cysteines. This
cysteine residue is located fourth from the end in a CaaX or CxC motif, adjacent
to the polybasic region of the protein chain (Weivoda & Oursler, 2014; Zhang &
Casey, 1996). Without prenylation of FPP and GGPP, the small GTPases do not
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localize correctly in the cell membrane to exert their specific actions, relying on
FPP and GGPP as anchors in the cell membrane (Zhang & Casey, 1996).
Without properly functioning small GTPases, many functions of the osteoclast
and resorption are impaired: vesicle transport, cellular polarization, actin
reorganization, and overall cell activity (Coxon, Thompson, & Rogers, 2006;
Crockett et al., 2011; Ory, Brazier, Pawlak, & Blangy, 2008; Rogers et al., 2000).
Dunford and colleagues (2001) examined zoledronate in vivo and in vitro. They
found that its antiresorptive potency stems from the nitrogen atom within the
heterocyclic rings inhibiting FPPS rather than the degree of cellular uptake or
pharmacokinetics of zoledronate. Two other pharmacodynamic factors of
bisphosphonates include the critical inhibition of the dissolution of HAP mineral,
and the different binding affinity profile of each bisphosphonate based on its
chemical structure (Nancollas et al., 2006; Russell, 2011).
The great cost of conducting human and rodent science on the ISS has
led researchers to pursue ground analogs to simulate conditions of microgravitylike weightlessness. One such protocol is the 30° hindlimb unloading (HU) model
in mice and rats (Morey-Holton & Globus, 2002). Musculoskeletal disuse
simulates weightlessness, which increases osteoclast activity and decreases
bone structure (Heer, Baecker, Mika, Boese, & Gerzer, 2005; Nabavi, Khandani,
Camirand, & Harrison, 2011; Tamma et al., 2009). Animal studies allow
techniques of both destructive mechanical testing and radiographic structural
morphology scanning. These studies also have scientific value in enabling
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researchers to control study variables such as duration, unloading, age, drug
administration, and temperature.
Lloyd et al. (2008) provided evidence that, in a growing mouse model (6
weeks old), an effective antiresorptive dosage of zoledronate is 45 µg/kg to
counteract skeletal hindlimb unloading and to maintain bone stiffness. Pozzi and
colleagues (2009) examined zoledronate’s efficacy on bone remodeling in the
growing mouse model (5 weeks old), reporting that 100 µg/kg was no more
effective of an antiresorptive than 50 µg/kg. Utilizing a rat immobilization model
with the right hindlimb affixed to the abdomen, Khajuria, Razdan, and Mahapatra
(2015) found a zoledronate dosage of 50 µg/kg to be effective at countering the
deleterious impact of limb immobilization on mechanical properties.
Potential negative side effects on the mechanical and structural properties
of astronaut bone should be examined when heightened turnover, high-force
exercise, and antiresorptive bisphosphonate drug treatments are combined. This
is of note due to clinical concerns of atypical femoral fractures along the
diaphysis and osteonecrosis of the jaw with long-term bisphosphonate use
(Iwata, Mashiba, Hitora, Yamagami, & Yamamoto, 2014; Reid, 2009; Shane et
al., 2010; van der Meulen & Boskey, 2012). Zoledronate is an attractive
countermeasure candidate due to its intravenous 6-month injection timeline.
Other bisphosphonates require a weekly oral dose and have several negative
drawbacks such as possible gastrointestinal intolerability, myalgia, and arthralgia
(LeBlanc et al., 2013; Silverman & Christiansen, 2012).

7

Work by Currey (2012) illustrated the principle that as the degree of
mineralization increases in bone, there is a corresponding linear increase in
stiffness. As a bone becomes more mineralized, it becomes stiffer, but at a
certain point there is a rate of diminishing returns. Currey generated data that
argued the elastic stiffness and plasticity of bone can have an inverse
relationship. If a bone becomes too stiff from overmineralization, it becomes
more brittle and less tough. Brittleness is an inverse measure of plasticity.
Brittleness is also measurable in terms of reduced strain required to initiate
permanent deformation, the point where bone structural integrity yields.
The organic bone matrix, with its major constituent of collagen, is
disproportionately responsible for bone plasticity and contributes to toughness.
Small changes to the quality of bone collagen would have little effect on bone
stiffness, with mineral HAP having around 114 GPa (gigapascals) and collagen
1.5 GPa (Zioupos, Currey, & Hamer, 1999). Because collagen is composed of
numerous organic constituents such as crosslinks and water, changes in
collagen quality and composition could have dramatic effects on bone toughness
and plasticity. From the yield point onwards, it is the collagen and the organic
matrix that absorb and disperse energy until abject failure of the bone (Burr,
2002; Currey, 2012; Currey, Brear, & Zioupos,1996).
Zoledronate treatment results in greater bone mineralization and retention.
The purpose of this study was to assess the effects of zoledronate on bone
mechanical and structural properties of bone during simulated weightlessness. It

8

was hypothesized that the zoledronate-treated mice experiencing simulated
weightlessness would increase their whole-bone elastic stiffness but have
diminished mechanical plasticity, making the bones stiffer but more brittle.
Objective
The objective of this work was to examine the effect of zoledronate on
bone mechanical and structural properties in an experimental model designed to
mimic spaceflight weightlessness. The 30° hindlimb unloading model was used
to mimic the effects of weightlessness and induce musculoskeletal disuse in
mice. The expectation is that this work will add to the body of knowledge to
enhance the development of countermeasures to enable prolonged space
exploration in the future.
Delimitations
This study was focused on the mechanical and structural impact of
hindlimb unloading musculoskeletal disuse and zoledronate administration in
mice. Treatment effects were examined ex vivo using the left femur from the
animals. All mice were of the same age (16 weeks), gender (male), genetic bred
strain (C57BL/6), and they were subject to similar housing, feeding (ad libitum),
and handling.
Limitations
This experimental model was designed to simulate the conditions
astronauts experience in spaceflight. Although mice and humans are both
mammalian species, there are a few significant differences. They include the
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size of human versus mouse bone and the growth plate of bones. Unlike the
human growth plate, which closes at maturity, the mouse growth plate does not
fully attain closure at any point in the lifespan. Additionally, mouse cortical bone
presents with lamellae and adjacent osteocytic lacunar networks rather than the
osteonal Haversian canal networks found in human cortical bone. Lastly, the
mechanical properties of toughness and plasticity of bone were measured in this
study. There is consensus in the field that the behavior and characteristics of
collagen are responsible for the plasticity of bone (Burr, 2002; Viguet-Carrin,
Garnero, & Delmas, 2006). Without an assay for collagen measurements, a full
characterization of the molecular changes due to the treatment is not possible.
Overview
This thesis is divided into five chapters. Chapter II presents background
on general bone structure, the femurs of both humans and mice, the hindlimb
unloading model, micro-computed tomography (µCT) scanning, and the 3-point
(3-pt) bending mechanical test. Chapter III provides specifics on study design,
specimen preparation, data collection procedures, and statistical analysis.
Results are presented in Chapter IV, followed by Chapter V, which includes
conclusions, a discussion of the significance of the findings, and
recommendations for future work.

10

Chapter II
Review of Literature
Bone Components
The skeleton has a hierarchical level of organization. While there are
variations between species in the shapes of their bones, all bones on the gross
level are considered to be either long, short, flat, sutural, pneumatic, irregular, or
sesamoid. When a long bone is examined, there is identification of distal and
proximal epiphyses separated by the intervening diaphysis. In a femur, there is a
distal region known as the metaphysis, which is rich with a lattice, strut-like plate
network referred to as cancellous bone. This structure is extremely porous, with
the thickness of individual trabeculae measuring 100 to 300 µm in humans (Fratzl
& Weinkamer, 2007). Encapsulating the bone’s cancellous compartment is a
sturdy layer with low porosity, known as cortical bone.
Mice provide researchers a remarkable model to explore the biology of the
mammalian skeleton and enable extensive studies of disease. The model is
utilized to understand structural and mechanical properties of bone (Jepsen,
Silva, Vashishth, Guo, & van der Meulen, 2015). Despite a big difference in
lifespan (human ≈ 80 years, mouse ≈ 2 years), they both present with analogous
age-related bone changes at similar points in their respective lifespans
(Ferguson, Ayers, Bateman, & Simske, 2003; Halloran et al., 2002). A few
aspects of the mouse model are of note. Mouse bones have different anatomical
skeletal arrangements and ambulate in a quadrupedal manner. This translates
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to a specific distribution of skeletal stresses and strains based upon ground
reaction forces and muscles generating forces according to ambulatory patterns
(Figure 1).

Figure 1. Mouse femoral anatomy. Internal view of a left mouse femur from a
coronal plane slice at the third trochanter.
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When examining the internal coronal plane view of a left mouse femur one
sees the outermost radius is comprised of cortical bone, with a corresponding
outermost connective tissue layer known as the periosteum. Spanning the length
of the diaphysis is a central cavity known as the medullary cavity, which is lined
with a bony connective tissue layer called the endosteum. Of note, mice present
with a prominent third trochanter, which differs from that of normal human
anatomy. The third trochanter of the mouse receives tendons from the hindlimb
muscles, which then insert into the third trochanter’s periosteal layer (Hamrick,
McPherron, Lovejoy, & Hudson, 2000).
At the tissue level, there are spatial arrangements that differ between
cortical bone and concentrated sections of individual trabeculae of cancellous
bone. In different animals, various degrees of cortical organization are seen.
This organizational network of bone can be classified as being either woven
(more chaotic, irregular), lamellar (organized smoothly, parallel structure), or
osteonal (concentric lamellar bone) (Wagermaier, Klaushofer, & Fratzl, 2015).
Each organization depends upon the configuration of individual collagen
molecules, mineralization, and the extrafibrillar matrix consisting of proteoglycans
and noncollagenous proteins, which also impact the relative mechanical
properties of each bony tissue (Doblaré, García, & Gómez, 2004).
Human cortical bone predominantly displays osteonal Haversian
networks, with concentric lamellae (layers of bone matrix) wrapped around a
central Haversian canal. Mouse bone is also characterized as lamellar bone but
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not to the same magnitude of concentric organization. Lateral and medial to the
lamellar mouse cortical bone, layers of fibers extend toward the endosteal and
periosteal surfaces. Through three different microscopy techniques, Kerschnitzki
and colleagues (2011) concluded that, in the femur of the mouse, this cortical
endosteal and periosteal bone deposition pattern corresponds to an alignment of
the osteocytic cytoplasmic processes and the structural arrangement of the
collagen matrix. The differing pattern between mouse and human bone is an
understood condition when drawing mechanobiological conclusions from
scientific research.
There are three major bone cell types: osteoblasts, osteocytes, and
osteoclasts. Osteoblasts are mononucleated cells derived from mesenchymal
stem cells via the osteoprogenitor pathway (Blaber et al., 2014). They are critical
in bone formation via an exocytotic release of Type I collagen as well as many
noncollagenous bone proteins (Neve, Corrado, & Cantatore, 2011; Orriss,
Burnstock, & Arnett, 2010). Before HAP minerals are deposited, the organic
cartilaginous layer is referred to as an osteoid. At the conclusion of
osteogenesis, levels of the osteoblast-dependent alkaline phosphatase mRNA
decline drastically, followed by around 70% of mature osteoblasts undergoing
apoptosis (Neve et al., 2011). Some of the osteoblasts become incorporated into
the newly formed osteoid that they secreted and differentiate into osteocytes
(Franz-Odendaal, Hall, & Witten, 2006; Manolagas, 2000).
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Osteocytes are contained within protective cavities, referred to as lacunae
and form an interconnected network of canalicular cytoplasmic projections within
the bony matrix. These networks allow passageway of metabolites and are
thought to mediate responses to mechanical loading. Cancellous tissue has a
considerably higher porosity than cortical, with most cortical porosity accounted
for by the lacunae, vessels, and nerves. Osteocytes comprise 90-95% of all
bone cells (Bonewald, 2011).
Responsible for bone resorption, osteoclasts are usually multinucleated
and develop into bone-specific macrophages from the hematopoietic cell lineage
of differentiating monocyte/macrophage precursors (Boyle, Simonet, & Lacey,
2003). Functioning osteoclasts undergo a stepwise progression to create an
acidic resorption lacunar pit atop the bony matrix. Osteoclasts first attach and
begin cellular polarization, initiating the bone resorption process, followed by a
cessation of bone resorption (Mellis, Itzstein, Helfrich, & Crockett, 2011). The
polarization/attachment stage involves a rearrangement of the cell’s cytoskeleton
to form a “sealing zone” formed by adhesive podosomes on the bone matrix
surface (Lakkakorpi & Väänänen, 1996; Luxenburg et al., 2007). Osteoclasts are
motile cells that migrate over the bony matrix and rely on the ability of these
podosomes to disassemble and assemble quickly (Luxenburg, Parsons, Addadi,
& Geiger, 2006; Mellis et al., 2011).
The full breadth of molecular signals and energy pathway downregulatory
mechanisms that result in podosome disassociation, a halt to cell motility, and
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cessation of resorption at the lacunar pit are still being investigated (Mellis et al.,
2011). There are several physiological regulators that influence the final
cessation of osteoclast resorption. The hormones calcitonin, vitamin D3 (1,25 Vit
D3), parathyroid hormone (PTH), and estrogen all have a function in osteoclast
activity, differentiation, regulation and, ultimately, cessation of osteoclast
resorption (Crockett et al., 2011). Calcitonin is secreted from the parafollicular
cells of the thyroid gland, and, when it is inhibited from binding to its osteoclastic
cellular receptors, there are significant downstream intracellular effects. These
include reductions in ruffled border amount, inhibition of endocytosis of bone and
mineral at the ruffled border, and a reduction in osteoclast number over time
(Chambers & Magnus, 1982; Stenbeck, Lawrence, & Albert, 2012; Zaidi,
Inzerillo, Moonga, Bevis, & Huang, 2002). As previously mentioned, nitrogencontaining bisphosphonates such as zoledronate have very specific intracellular
effects through action on the FPPS pathway within the osteoclast cell.
The Hindlimb Unloading Model
The present study used the hindlimb unloading mouse model to mimic
microgravity-like weightlessness. In effect, the model induces musculoskeletal
disuse in mouse hindlimbs. The model is a longstanding, validated, rodentspecific one used to mimic the musculoskeletal effects experienced during
spaceflight (Morey-Holton & Globus, 1998). Adult mice incur a net loss of bone
during both spaceflight and in hindlimb unloading ground analog model. Much of
the early research related to bone in spaceflight used young, pubescent rats,
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which presented with a halt to bone growth rather than a net loss of bone
(Globus & Morey-Holton, 2016).
Hindlimb suspension allows for unrestricted forelimb movement. The
model does not produce excessive stress to the animals, as demonstrated by
bodyweights of HU mice remaining similar to those of control animals (MoreyHolton & Globus, 2002). Similar skeletal structural changes due to aging occur in
both mice and humans; thus, mice are an appropriate model to understand agerelated bone losses (Ferguson et al., 2003; Halloran et al., 2002).
Mice from 3 to 6 months of age are considered mature and
postpubescent. This age range is physiologically comparable to humans
between 20 and 30 years of age (Flurkey, Currer, & Harrison, 2007).
Postpubescent mice of 16 weeks were used in the present study. The age of the
mice at the end of the 3 week study placed their age group analogous to humans
in their middle 20’s. Astronauts from the National Aeronautics and Space
Administration (NASA) have an age range for their astronaut corps between 25
and 55 years (Orwoll et al., 2013).
Mechanical Testing and the Three-point Bending Configuration
Bending tests are useful for assessing the mechanical properties of rodent
bones. The small size of mouse femurs makes machine working of specimens
difficult. Bending tests centered on a diaphyseal section of the mouse femur are
common in the literature (Jepsen et al., 2015). The mass of bone at the
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diaphysis is predominately cortical bone. The bone receives a monotonic load at
a certain rate of displacement to induce bending until the specimen fractures
(Fyhrie & Christiansen, 2015). Bending tests cause the side receiving the
applied force to experience compression, while the opposite side experiences
tension. Bone is weaker in tension and usually fails on the tensile side first
(Turner & Burr, 1993). Figure 2 provides an illustration representing the 3-pt
bend test.

Figure 2. Three-point bending configuration. Configuration of the 3-pt bend test
along the diaphysis of the femur. F is the direction of the force applied, and d is
the resulting displacement (mm) from beginning of force application until
completion of test. The test is performed at exactly midpoint of the span length
of the pins (5 mm), signified by L, just inferior to the third trochanter. Data
collected from this test report the force and displacement measurements until the
bone fully fractures.
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Precise reporting of subject and testing apparatus dimensions is crucial to
enable accurate comparisons across studies. An important consideration of the
3-pt bend test is the orientation of the femur either anterior-posterior or posterioranterior. Opposing sides of the in vivo mouse are subjected to differing stresses
from the insertion and actions of muscles and vector of gravity. This results in
differing strength properties of the tested bone on different sides of the femur
(Jepsen et al., 2015). Table 1 summarizes the literature for pertinent bending
studies. Of the 15 studies examined that reported these data, eight had femurs
presented with the anterior surface facing down and seven had femurs
presenting the reverse. The femur was positioned anterior face down for this
study. This was intended to expose the anterior face of the femur to failure from
applied forces first (in tension).
Another important detail of the test is the span length between the bottom
two supports. Based on the need to apply beam theory equations to arrive at
tissue-level properties, a section of the femur most cylindrical was necessary
(Gere & Timoshenko, 1984; Turner & Burr, 1993). A 5 mm span width between
the two bottom supports was chosen just distal to the third trochanter on the
lateral border of the femur. This choice agrees with literature (Akhter et al., 2000;
Akhter, Fan, & Rho, 2004). During this study, calipers were used to ensure
precision.
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Table 1
Femur Bending Methods
Animal

Type

Orientation

Span Length

Load Rate
(mm/s)
Reference

Rat

4 point

Ant-Post

not reported

0.5

Bonadio et al. (1993)

Mouse

3 point

Ant-Post

5 mm

0.05

Akhter et al. (2000)

Rat

3 point

Post-Ant

13 mm

0.166

Ferretti et al. (1993)

Rat

4 point

Ant-Post

not reported

0.5

Smith et al. (2000)

Mouse

3 point

Post-Ant

7 mm

0.3

Silva et al. (2006)

Mouse

3 point

Ant-Post

6.5 mm

0.155

Jämsä et al. (1998)

Mouse

4 point

Post-Ant

4 mm

0.033

Brodt et al. (1999)

Mouse

3 point

Ant-Post

5 mm

0.05

Akhter et al. (2004)

Mouse

3 point

Post-Ant

7 mm

0.033

Wergedal et al. (2002)

Mouse

3 point

Ant-Post

10 mm

0.2

Schriefer et al. (2005)

Rat

3 point

Ant-Post

not reported

0.1

Ke et al. (1998)

Mouse

3 point

Ant-Post

6 mm

0.5

Voide et al. (2008)

Mouse

3 point

Post-Ant

10 mm

0.033

Spatz et al. (2013)

Mouse

3 point

not reported

8 mm

0.0833

Lloyd et al. (2008)

Rat

3 point

Post-Ant

13 mm

0.166

Ferretti et al. (1993)

Mouse

3 point

not reported

4 mm

0.166

Kodama et al. (2000)

Mouse

3 point

not reported

5 mm

0.5

Turner et al. (2000)

Mouse

3 point

Post-Ant

7 mm

0.033

Wergedal et al. (2005)
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Whole-bone mechanical properties are based on forces applied and
displacement incurred on a specimen. A force-displacement curve may be
graphed from the data and divided into two distinct regions: the elastic
deformation and plastic deformation regions (Figure 3). The initial slope of the
curve of the elastic region is known as stiffness (N/mm), a measure of how much
a bone can deform without sustaining permanent deformation. The bone
deformation is transient; it returns to its original shape. The elastic and plastic
regions of the force-displacement curve are divided by a yield point, N. This is
the peak of the initial linear stiffness slope when forces on the bone result in
microcracks such that permanent damage occurs. The point where a bone can
sustain the greatest force is the ultimate force (N). Postyield displacement (PYD)
is a measurement of the amount of permanent deformation prior to fracture.
Finally, there is a fracture point force, which is where the last of the force is
applied before a complete fracture of the bone (Jepsen, Pennington, Lee,
Warman, & Nadeau, 2001; Turner & Burr, 1993).
The size of the bone tested is of critical importance for reliable whole bone
mechanical tests. Tissue-level mechanical properties of bone are sizeindependent, enabling two different bones to be compared (Jepsen et al., 2015).
This is accomplished by converting the raw force-displacement data into a tissuelevel stress-strain curve by using mechanical engineering equations, which are
shown in Figure 4 (Gere & Timoshenko, 1984; Turner & Burr, 1993).
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Figure 3. Force-displacement curve. Mechanical properties and notable
attributes from the force-displacement curve produced by a 3-point bending test.
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Figure 4. Beam theory equations for estimating bone material properties from
bending tests. Stress (σ, sigma, force/area) is the applied load per unit of crosssectional area. Strain (ε, epsilon, [elongated length – original length]/original
length) is the measurement of percent change in length, or relative deformation.
Elastic modulus (E, N/mm2 = MPa, megapascal) is the resistance to permanent
deformation at a tissue-level, and corresponds with the whole-bone parameter of
stiffness. F is applied force, d is displacement, L is span length, c is the distance
from the center of mass, I is the cross-sectional moment of inertia.
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The whole-bone displacement (mm) or tissue-level strain (%) beyond the
yield point up until the fracture point is a measurement of the ductility of a
material (Jepsen et al., 2015) (Figure 3). When a material lacks much postyield
region, it is referred to as a brittle material. Chalk is an example of a brittle
material with little plasticity. In a brittle material, once the elasticity of the material
is breached at the yield point, very little energy is required for fracture failure.
The area under the force-displacement curve is a measurement of energy,
known as work-to-fracture (Nmm; toughness) (Jepsen et al., 2001, 2015; Turner
& Burr, 1993). The postyield displacement, postyield strain, and work-to-fracture
(toughness) were all examined in this study.
Structural Imaging of Bone Morphometry
It is important that the materials and geometric morphometry of bone
specimens are analyzed along with mechanical testing. The structure influences
the mechanics. The structural measurements of cortical and cancellous bone
were measured for this study, and established guidelines for micro-computed
tomography (µCT) were taken into consideration (Bouxsein et al., 2010). In this
study, µCT evaluated bone morphology and microarchitecture ex vivo. Data
were acquired of the attenuation of X-rays from multiple angles. These data
were then compiled to reconstruct 3-dimensional images that represented the
spatial and density characteristics of the material. Bone is a composite material
of both inorganic and organic components. The method of µCT specifically
elucidates a bone’s structure and morphology with X-rays attenuating through the
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inorganic phase of calcium-phosphate in the form of semi-crystalline HAP with
carbonate, accounting for 35-45% of bone volume. The other primary
components of bone are collagen, with its enzymatic and nonenzymatic
crosslinks (35-45% bone volume) as well as water (15-25% bone volume)
(Granke, Does, & Nyman, 2015). Both 2-dimensional (2D) and 3-dimensional
(3D) µCT architecture were examined in this study, translating into both volume
and areal outcomes.
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Chapter III
Methods
This study was conducted in the Bone and Signaling Laboratory at the
NASA Ames Research Center. The purpose of the study was to assess bone
properties in the presence of zoledronate and simulated weightlessness. This
was accomplished through software analysis of bone geometry from µCT scans,
ex vivo mechanical testing, and utilization of mechanical engineering equations
for tissue-level material properties.
Ethics Statement
All animal experimental procedures were approved by the Institutional
Animal Care and Use Committee at the NASA Ames Research Center (protocol
NAS-13-004-Y1), with tissue use approved by the San José State University
Institutional Animal Care and Use Committee (protocol 2015-E). All animal
handling procedures were followed according to the U.S. National Institutes of
Health Guide for the Care and Use of Laboratory Animals (National Research
Council (US) Committee for the Update of the Guide for the Care and Use of
Laboratory Animals, 2011).
Animals and Study Design
Thirty-two male, postpubescent, 16-week-old C57BL/6 mice (Jackson
Laboratory, Bar Harbor, ME) were housed at the NASA Ames Research Center.
The animals were randomly divided into four groups (n = 8). Body mass (g) was
measured and used to distribute mice evenly throughout the four groups. In the
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ambulatory group (NA), eight were injected with saline vehicle (VEH) while
another eight were injected with the same volume of zoledronate (ZOL, 45 µg/kg,
from Sigma Aldrich). In the hindlimb unloaded (HU) group, eight received saline
vehicle (VEH) while another eight received the same volume of ZOL (45 µg/kg).
The subcutaneous injections were performed at the lower back 3 days prior to
hindlimb unloading, with these days also serving as the cage acclimation period.
All animals were monitored at least twice a day, maintained on a 12/12 light/dark
cycle (6 am to 6 pm). The mice were given standard laboratory food chow (Lab
Diet 5001, Purina Mills, St. Louis, MO) and water ad libitum throughout the
duration of the study. Normal behavior of grooming and trauma-free coats were
observed.
Hindlimb Unloading
The HU group underwent 3 weeks of hindlimb disuse according to the
method of Morey-Holton and Globus (2002). This technique suspended the
animal at 30° with tail traction while permitting free movement of the forelimbs.
Mice in the NA group were individually housed for the same period of time to
mimic the isolated stress of the HU group.
It is of note that in a separate component of this study we utilized the
same mice and investigated the effects of in vivo mechanical loading on the right
tibia in conjunction with ZOL and HU administration. All of this study’s animals
underwent applied mechanical loading to their right tibias three times a week for
3 weeks. While anesthetized, mechanical loading involved a 9N pulse in
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compression (~1300 µstrain), applied 60 times with 5 s intervals on the mouse
knee, transmitting force uniaxially through the tibia to the stationary positioned
calcaneus. The entire process of anesthetization, loading, recovery, and
immediate return to HU lasted, on average, 12 min per loading session. Mice
were removed from the HU apparatus during compression application, which was
administered after mice were anesthetized with 2% isoflurane. Additionally, each
animal in this study had its left tibia analyzed via dynamic and static
histomorphometry ex vivo.
At the time of dissection, animals were momentarily ambulatory during
anesthetization, with subsequent euthanizing via CO2 inhalation. Left femurs
were wrapped with PBS-soaked gauze (with calcium and magnesium chloride)
and stored at -20ºC.
Microcomputed Tomography (µCT) Scanning
Prior to scanning, femurs were permitted to thaw at 4°C overnight in PBS,
with an additional acclimation time of 20 min prior to scanning at room
temperature. All left femurs were scanned using µCT to quantify the 2D and 3D
microarchitecture (SkyScan 1174 µCT scanner, Kontich, Belgium). All whole left
femurs were scanned at the low resolution isotropic voxel size of 17.3 µm per
pixel to provide cortical bone data from the midsection of each diaphysis. To
investigate cancellous bone, all distal metaphyses sections were scanned at the
high resolution isotropic voxel size of 6.7 µm/pixel. Specimens were mounted
into the low density X-ray scanner, with the bone fixed within an Eppendorf tube.
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To ensure hydration during the scan, PBS-soaked gauze was wrapped around
the femurs. A 0.5 mm aluminum X-ray filter was affixed in the line of sight
between the X-ray source and the specimen, with the X-ray beam scanner
operating at 50 kV and 800 µA. Scan settings were set to an exposure time of
3.5 s per frame, with the images averaged across two captured frames for every
rotated step of 0.5° and the bone rotating throughout an entire angular span of
180°.
Reconstruction
Scans were reconstructed into 2D cross sections using the software
NRecon (SkyScan, v.1.6.10.2). Dynamic range settings across all samples were
consistent after the upper limit of the linear attenuation coefficient threshold was
determined to be 0.15. Reconstruction parameters additionally included a beam
hardening correction of 30% and a ring artifact correction of 4.
Morphometric Analysis
Two rotational alignment protocols were developed to quantify the
morphometric data from the mid-shaft diaphysis and the distal metaphysis.
Using the reconstructed images, the low and high resolution femoral images
were aligned to ensure a consistent rotation in the coronal, sagittal, and
transverse planes across all samples using the SkyScan software DataViewer
(v.1.5.2, Figure 5). The distal growth plate and greater trochanter were selected
as consistent anatomical landmarks for the low-resolution, whole femur protocol.
This ensured that the diaphyses were parallel in the Y-axis and the cortical bone
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was upright in the Z-axis, enabling accurate moment of inertia data for
postprocessing analysis. A similar protocol was devised for consistency in the
high resolution images of the distal metaphysis. Before the regions of interest
were selected for contouring, a lower and upper threshold of the foreground from
the background into a binary image indicating bone was determined using 15
samples. The selected values were used across all samples in the SkyScan CTanalyser software (CTAn, v.1.10). This point in the imaging process was also
where the pixelization of the scans was analyzed quantitatively to determine
tissue mineral density (TMD).
For the 6.7 µm/pixel scans, the distal metaphysis volume of 1500 µm was
contoured, based on a 410 µm offset from the growth plate. For the 17.3
µm/pixel scans of the whole femur, a 5 mm span width was identified for use in
the 3-pt bending tests in DataViewer starting at the most distal portion of the third
trochanter of the mouse where cortical bone thickness contours were uniform.
Measurements
The program ImageJ was used to increase the accuracy of bone
placement upon the pins. Based upon imaging, all samples were labeled for a 5
mm span descending inferiorly from the third trochanter. This method ensured
precise femur placement to increase the reliability of mechanical testing (Figure
6).
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Figure 5. DataViewer protocol of mouse femoral scans. Sagittal femur view on
left and coronal femoral representation on right. A protocol was developed to
ensure consistent positions across all µCT samples with regard to 2D
measurements and, especially, the moments of inertia. Notice the condyles of
the femur presenting in both views inferiorly, with the femoral head and greater
trochanter presenting superiorly. Take note of the X, Y, Z orientations which
were adhered to across all subject scans based on the growth plate center,
diaphysis, femoral neck, and greater trochanter.

Figure 6. Coronal view of ImageJ mouse femoral scan.
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Mechanical Testing
Monotonic 3-pt bending mechanical tests to failure were conducted on all
left femurs at a constant displacement rate of 0.01 mm/s (Bose ElectroForce
3220 Series II with 225 N load cell; Bose Corporation, Eden Prairie, MN, USA).
Determination of 5 mm and 1 mm sections of the femoral diaphysis was made by
examination of the 17.3 µm/pixel low resolution images. ImageJ was used to
create high resolution image files to increase the accuracy of specimen
placement on the lower two spans. On the evening prior to mechanical testing,
the femurs were transferred from a -20°C to a 4°C freezer. Samples were
allowed 20 min for thawing in room temperature (25°C) PBS. The anterior
surface of the femur was placed in contact with the lower two pins, with a 5 mm
span between pins. Calipers were used to ensure accuracy (Figure 7).
Statistical Methods
All statistical analyses were performed using JMP (v.8, SAS Institute,
Cary, NC). To enhance accurate analysis of the treatment groups on the bone
structure and mechanical indices, the influence of body mass was taken into
consideration. A linear regression with two independent variables (HU/NA,
ZOL/VEH) and a bodyweight variable was conducted. All interactions were
analyzed between all parameters (HU, NA, ZOL, VEH, BW). If there were no
interactions with bodyweight (homogeneity of regressors), then interactions were
removed and a two-way ANCOVA was performed. The least squares means
and standard deviations are reported.

31

Figure 7. Lateral view of three-point bending test apparatus. Notice the
condyles on the right side of the mouse femur facing upwards.
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Chapter IV
Results
This study investigated the effects of zoledronate on bone mechanical and
structural properties during simulated weightlessness as a model of spaceflight.
It was hypothesized that the zoledronate-treated mice experiencing simulated
weightlessness would increase their whole-bone elastic stiffness but have a
diminished mechanical plasticity, making the bone more brittle and less tough.
Bodyweight Analysis
Throughout the study, mice were weighed twice a week to monitor
bodyweight. At the onset, body mass was measured and used to distribute mice
by weight evenly throughout the four treatment groups. After a 3-day acclimation
period, the weight on the first day of HU was taken as the basal bodyweight (g),
and the measurement during the last week of HU was taken as the final
bodyweight (Day 17). As shown in Figure 8, bodyweight was significantly lower
in HU animals from basal to final bodyweight (-10.5%) compared to NA controls
(-3.1%, p = 0.0001). No changes were observed after ZOL treatment. This
impactful relationship of body mass and HU treatment necessitated use of the
general linear model of analysis of covariance (ANCOVA). Treatment effects
were analyzed with bodyweight as the covariate. In terms of bodyweight, these
data suggest that a certain aspect of hindlimb unloading resulted in bodyweight
changes. Hindlimb unloading itself may have caused less feeding due to stress,

33

or perhaps the anesthesia administration in combination with axial compressions
on the right tibia induced systemic stress as well.
In the review of the 3-pt bending test data, results from five animals were
missing during the tabulation and data transformation process. The final sample
sizes for the mechanical testing ANCOVA process were: NA/VEH: 6, NA/ZOL: 7,
HU/VEH: 7, and HU/ZOL: 7.
The mid-diaphyseal cortical µCT data had four datasets with substantial
visual streaks obscuring scans and reconstruction noise, and one sample was
fractured near the diaphyseal midpoint during dissection. Those data were
removed, and the final sample sizes for the µCT cortical structure ANCOVA
process were: NA/VEH: 6, NA/ZOL: 7, HU/VEH: 7, and HU/ZOL: 7.
A few samples were removed for reconstruction noise and µCT scan
streaks from the distal metaphyseal cancellous datasets. Additionally, a final
review prior to ANCOVA showed a single animal’s cancellous parameters
exhibiting abnormally high results in bone volume fraction, BV/TV; trabecular
thickness, Tb.Th; and trabecular number, Tb.N. This animal was in the NA/VEH
group. A Grubbs Extreme Studentized Deviate Test categorized the BV/TV
results for this animal as an outlier (p > 0.05). The same animal presented with
normal bone levels in its cortical µCT scan. Only cancellous data for that animal
were removed. The final sample sizes for the µCT cancellous structure
ANCOVA process were: NA/VEH: 5, NA/ZOL: 7, HU/VEH: 7, and HU/ZOL: 6.
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Figure 8. Final bodyweight analysis. Weight on day 17, during the last week of
unloading. Values are M ± SD.

Cancellous Structure, Tissue Mineral Density
Cancellous structure and tissue-level density of the distal femoral
metaphysis were measured by µCT (6.7 µm/pixel). As a main effect, ZOL
improved the cancellous tissue at this region for each parameter over VEH (p =
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0.001, Table 2). Relative to vehicle, ZOL increased the bone volume fraction
(BV/TV) by 7% and tissue mineral density (TMD) by 8%. An interpretation of
these data confirms the efficacy of ZOL for maintaining bone structure and
mineral content in the distal femoral metaphysis by preventing bone resorption
via osteoclast inhibition or perhaps in conjunction with prevention of osteocyte
apoptosis, a topic still being investigated (Plotkin, Bivi, & Bellido, 2011).
Hindlimb unloading had no statistically significant main effect, despite a
28% BV/TV reduction in the vehicle-treated group. A subsequent analysis
revealed there was a lack of statistical power via loss of animals and the
ANCOVA process to homogenize the regressor relationship. Testing the
assumption of homogeneity of regressors for HU and bodyweight in the
ANCOVA process presented with two trends toward an interaction for trabecular
separation (p = 0.07) and trabecular number (p = 0.09). This indicates a trend
toward an interaction effect of HU by bodyweight in the VEH animals but not in
ZOL. A post-hoc power analysis was performed, and a sample size of 11 would
have been needed to detect this difference for trabecular number with 80%
power. Taken together, these data suggest that bodyweight losses influenced
the skeletal response to disuse in the cancellous tissue, with ZOL preventing
bone loss.
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Cortical Structure, Tissue Mineral Density
Cortical architecture and mineral density at the subtrochanteric femoral
diaphysis were measured by µCT (17.3 µm/pixel). With no significant impact on
cortical TMD, ZOL significantly increased cortical thickness (p = 0.007, Table 3),
though with only a marginal biological increase of 2% compared to VEH.
Hindlimb unloading had no statistically significant main effects, despite a
10% cortical thickness reduction in the VEH group, indicative of a bodyweight
contribution. Interestingly, HU presented with two statistical trends toward an
effect for cortical bone area (p = 0.07) and the polar moment of inertia, J (p =
0.06). These trends indicate that simulated weightlessness tended to both
decrease cortical bone area and decrease the resistance to bending. As a
combined treatment, ZOL and HU resulted in a statistically significant interaction
with ZOL offsetting the trend of HU cortical thickness losses (p = 0.04). Taken
together, ZOL conferred cortical thickness protection from losses in HU mice.
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Mechanical Properties, Stiffness, Plasticity
Mechanical properties were determined using 3-pt bending tests of mice
femurs, and the data were analyzed at both whole-bone (mechanical properties)
and tissue levels (material properties, transformation by geometry). Table 4
presents results for each parameter. Figure 3 is a generalized forcedisplacement curve. Figures 9, 10, and 11 are graphical illustrations of treatment
main effects and combined treatment effects. For whole bone elastic
parameters, HU decreased stiffness (-30%, p = 0.05) compared to the NA control
condition (Figure 9). In contrast, ZOL increased bone stiffness (+28%, p =
0.0001) compared to vehicle (Figure 10). These data indicate that the dosage of
ZOL was effective in inducing an increase in stiffness; additionally, even in the
ANCOVA model, HU was effective in inducing stiffness losses. For stiffness, the
statistically significant interaction of HU and ZOL (p = 0.04, Figure 11) showed
the protective effect of ZOL in the presence of HU.
Taking geometry into account for tissue level parameters, ZOL resulted in
an increase in elastic modulus (+17%, p = 0.01, Table 4). Generally, stiffness
(whole bone) and elastic modulus (tissue level) parameters are analogous and
parallel measures of the ability of bone to absorb forces prior to suffering
permanent deformation. Interestingly, the elastic modulus showed no statistical
main effect of HU compared to NA nor an interaction of HU and ZOL (Table 4).
When the whole bone stiffness value was transformed its tissue level equivalent,
the results indicated that geometry was a factor in the HU stiffness effect
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compared to NA. In contrast, ZOL affected both whole bone and tissue level
(material) changes compared to VEH in terms of stiffness and elastic modulus.
Compared to VEH, ZOL increased yield force (+11%, p = 0.01, Figure 10)
as well as ultimate force (+17%, p = 0.0004), with a trend for ultimate stress, or
force per unit of bone area (+11%, p = 0.06). Hindlimb unloading resulted in a
trend (p = 0.07, Figure 9) of reducing yield force, yet not yield stress, compared
to NA. This trend of HU reducing yield force was in agreement biomechanically
with the result of HU reducing stiffness and indicated the geometric effect of HU
and a material effect for ZOL. These data confirm the hypothesis for elastic
stiffening.
In terms of plasticity on the whole bone scale, HU increased postyield
displacement compared to NA (+20%, p = 0.03, Figure 9). Zoledronate did not
increase postyield displacement, nor did ZOL significantly increase postyield
strain at the tissue level, both compared to VEH. This provides evidence to
reject the hypothesis that an increase in stiffness from ZOL would also result in a
decrease in plasticity. In fact, ZOL increased the total energy (work-to-fracture)
by 15% compared to VEH (p = 0.001), and this ZOL effect was also found for
postyield energy (+16%, p = 0.001). Taken together, these results indicate that
ZOL had a significant impact on increasing stiffness, yield force, and ultimate
force without affecting the plastic displacement. These increases in mechanical
properties seem to be the driving factors for the induced increases in both total
and postyield energy.
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Figure 9. Hindlimb unloading mechanical effects.
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Figure 10. Zoledronate mechanical effects.

Figure 11. Combined treatment effects.
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Chapter V
Discussion and Conclusions
The objective of this work was to examine the effect of zoledronate on
bone mechanical and structural properties in an experimental model designed to
mimic spaceflight weightlessness with a pharmaceutical countermeasure. The
premise for this study was driven by the concept of Currey (2012) that bone
stiffness and toughness have a relationship disallowing bone to be both very stiff
and very tough at the same time. The data used by Currey were based on
taxonomy and investigation of differing biomaterials to demonstrate how too
much stiffness from mineralization may reduce toughness. The 30° hindlimb
unloading model was used to mimic the effects of weightlessness and induce
musculoskeletal disuse in mice. Structural and mechanical properties of the
mouse femur were examined ex vivo. The hypothesis that zoledronate-treated
mice experiencing simulated weightlessness would increase their whole-bone
elastic stiffness, but have a diminished mechanical plasticity, making the bone
more brittle, was not fully supported by the data. Overall, ZOL prevented
negative effects of hindlimb unloading and unloading-induced bodyweight losses
on structure and mechanical properties of the mouse femur.
Hindlimb Unloading Effects
In this study, we used postpubescent, 16 week old C57BL/6 male mice in
hindlimb unloading to simulate weightlessness. The HU treatment decreased the
stiffness of bone (-29%, Table 4). Losses of bone were also found by Lloyd and
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colleagues (2008) in a similar HU model using growing female mice.
Interestingly, with 2 weeks of HU in 6 week old female C57BL/6 mice, Lloyd et al.
(2008) reported losses in stiffness from HU (-40%). Their loss of stiffness (in
growing mice) was more severe than those in the current study (in
postpubescent mice), which suggests growth suppression. This comparison
provides evidence that the age, as well as gender of the mice must be closely
considered when designing rodent studies. A growing bone subjected to HU is
still developing and may react by inhibition of the osteoblasts responsible for
bone formation. This may be due to a cross talk signal coupling effect, with a
subduing of osteoblasts via osteoclast inhibition (Crockett et al., 2011; Lloyd et
al., 2008; Mellis et al., 2011).
This study’s finding that HU resulted in a loss of stiffness is corroborated
by the marginal trending loss of cortical bone area and polar moment of inertia
(Table 3), yet with no change in tissue mineral density. The ability of ZOL to
prevent the loss of cortical thickness in HU animals also supports this claim.
Architectural measurements of bone have been found to correlate well with
mechanical properties, such as stiffness (Jepsen et al., 2015). Taken together,
these results were expected. A trending effect of HU in reducing bone area and
the polar moment of inertia provides an underlying mechanism for the reduced
bone stiffness.
The HU mouse model has previously been shown to display early and
pronounced cancellous architectural bone losses (Alwood et al., 2010; Amblard
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et al., 2003; Judex et al., 2004). This is in line with losses seen in weight-bearing
bones of astronauts (Collet et al., 1997; Lang et al., 2004; LeBlanc et al., 2000;
Vico et al., 2000). While not statistically significant, the raw data from the current
study show bone losses from HU compared to NA (Tables 2 & 3). Lower
statistical power and bodyweight loss may have contributed to the lack of
statistically significant results.
This effect of HU leading to greater resorption of cancellous bone due to
osteoclast activity has been shown in the literature. Shahnazari et al. (2012)
presented results describing the temporal-dependent activity of osteoclasts in
bone resorption over the course of 4 weeks of hindlimb unloading. In 24 week
old C57BL/6 mice (mature), an acute, but transitory increase of osteoclasts was
found in weeks 1 and 2, with the osteoclast-to-bone surface ratio returning to
normal by week 4. These results were consistent with bone volume (BV/TV) and
mineral losses. The increase in osteoclasts in weeks 1 and 2 led to the
significant bone and mineral losses toward the end of unloading. Iwaniec et al.
(2005) showed that after 1 week of HU of two different genetic strains (Wild-Type
and Transgenic ß1-integrin) of young female mice (9 weeks of age), osteoclast
surface area increased, consistent with a 30% reduction in cancellous bone in
the distal femur.
Compared to the NA group, the other impact of HU in this study was the
increase in postyield displacement, a measurement of ductility and bone
plasticity (Table 4). It is worthy to mention that compared to NA, HU did not have
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a statistically significant effect on for postyield strain, the concomitant tissue level
measure, though the data were similar for postyield displacement. This suggests
that geometrical changes, but not mineral concentration changes, contributed to
the HU effect. When whole bone force-displacement values are transformed to
the material level, geometry, but not mineral concentration, is factored into
various stress and strain measurements. While these data allow inferences
about one measurement of bone plasticity, a collagen assay would be required to
determine the full array of constituents at the material level, including the ratio of
matrix to mineral, the enzymatic crosslinks of collagen, and the water content
(Burr, 2002).
Summarizing the effect of HU on mechanical properties, HU reduced bone
stiffness, a measurement of bone’s elastic ability to sustain forces in the preyield
region without permanent deformation. Hindlimb unloading also resulted in an
increase in postyield displacement. The postyield region, both in terms of
displacement length and energy (areal) measurements, describes a bone’s
toughness and plasticity, respectively. Hindlimb unloading increased the
displacement the bone could withstand prior to full fracture, without a significant
impact on the bone’s ability to absorb energy prior to fracture (total energy or
postyield energy). Both postyield displacement and total energy are important
factors in bone toughness. In bone biomechanics, a tougher bone is more
resistant to fracture, separate from elastic behavior. On a structural level, the
increase in postyield displacement seen in HU animals suggests that the bone
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was able to sustain forces over a greater distance before full separation between
the lamellar layers of bone. This full fracture separation has been described as a
progressive accumulation of microfractures, leading to full breakage (Turner &
Burr, 1993).
Throughout much of the literature, stiffness is a commonly reported value
in mice and rat models. Energy absorption, toughness, and postyield
displacement have received less focus, with values often not reported in
biomechanical rodent studies. Attention has recently emerged for using the
rodent model to investigate bone plasticity. This is, in part, attributable to
evidence of reduced bone toughness as a characteristic in atypical femoral
fractures, one of the clinical concerns with long-term bisphosphonate use (Shane
et al., 2010; van der Meulen & Boskey, 2012).
Using the 3-pt bending method, Shirazi-Fard, Kupke, Bloomfield, and
Hogan (2013) found an increase in postyield displacement after the initial 28
days of unloading in rats (6 months old) compared to ambulatory controls. It is
worth noting that postyield displacement is simply one of the factors that can
describe plasticity of bone. The total energy incurred on bone, also called workto-fracture, is the total amount of energy under the force-displacement curve.
Besides postyield displacement, the placement of that curve also depends on the
magnitude of the yield, ultimate, and fracture forces. Shirazi-Fard et al. reported
that HU for 28 days had no significant effect on energy-to-max force (the amount
of energy accumulated to maximum force, the point synonymous with ultimate
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force). These results closely relate to the current study, with limitations of subject
selection and the selection of 3-pt bending on the tibia of the rat, not the femur of
the mouse. In contrast, Jing et al. (2014) investigated the rat femur in 3-pt bend
and a reduction in stiffness and total energy-to-fracture as well as reduced points
of yield and ultimate force in terms of displacement after 4 weeks of HU.
Zoledronate Effects
In this study, we utilized 45 µg/kg as the dose of ZOL and examined the
mechanical and structural effects on mouse bone. The objective was to replicate
the dose administered in the study of C57BL/6 mice conducted by Lloyd et al.
(2008). Results of the current study were in agreement; the dose of ZOL was
effective in conferring positive structural and mechanical results. In the current
study, ZOL greatly increased the stiffness of mouse bone over the course of 3
weeks compared to VEH, normal ambulatory, age-related controls (+28%). This
stiffness increase is consistent with the +21% increase found by Lloyd et al.
(2008). Zoledronate also had an effect on increasing the concomitant tissue
level property of elastic modulus in the current study compared to VEH. This
suggests that on the tissue level, similar elastic properties were conferred when
transformed by the geometry of the bone. There are several important
distinctions between the Lloyd et al. (2008) study and this project, such as age of
the mice (6 vs. 16 weeks old), gender (female vs. male), and the ZOL injection
latency period (2 weeks vs. 3 weeks). The selection of mature mice in the
current study was designed to provide a contrast with Lloyd et al. (2008),
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allowing for comparison of a similar dose of ZOL with the same genetic breed but
at differing ages.
Compared to VEH, there was a statistically significant effect of ZOL on
cortical bone in this study, but a biologically minimal effect in increasing cortical
thickness (+2%), and cortical bone area (+2%, Table 3). Zoledronate affected all
cancellous parameters (Table 2). Biologically, cancellous bone has been shown
to have turnover rates about 10 times that of cortical bone, which could explain
these data (Burr et al., 2003). Similar to HU expectations, it was anticipated that
3 weeks after a single ZOL injection, there would be a pronounced effect on
cancellous architectural struts. Compared to VEH, the percentage of cancellous
bone increased (BV/TV); the distance between struts decreased (Tb.Sep),
making the bone less porous; and the thickness per strut increased (Tb.Th).
ZOL increased the tissue mineral density of HAP in cancellous bone (Canc.
TMD), although not in the cortical compartment.
Compelling cellular mechanistic evidence of the actions of ZOL on mice
bone was provided by Kuroshima, Go, and Yamashita (2012). The authors
examined long-term effects of an extremely high dosage of ZOL (100 µg/kg, two
injections per week) on bone cells and bone microarchitecture in young male
mice. With a starting age of 8 weeks, the dosage regimen lasted for 13 months,
nearly half the lifespan of the animal. The authors confirmed that ZOL
significantly decreased the osteoclast surface area of bone, with no significant
effect on osteoblasts, compared to age-related controls. Through µCT, they
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demonstrated that ZOL had a protective effect on both cancellous and cortical
bone. Since the current study investigated the effect of ZOL on bone mineral, it
is interesting to note that with the extreme duration and dosage used by
Kuroshima et al. (2012), the mice did not display trabecular hypermineralization
with overly high tissue mineral density values of HAP in the cancellous bone of
the femoral metaphysis, consistent with the results of this study. While
Kuroshima et al. (2012) demonstrated zoledronate’s effect on cellularity and
quantity of bone, the quality of bone was not investigated. Notwithstanding, the
bones did not become hypermineralized, while increasing bone volume at the
distal metaphysis. This work on the cellularity and bone architecture after longterm ZOL treatment provides neither cellular nor bone architecture support for
the concept proposed by Currey (2012), which was predicated on bone
brittleness resulting from hypermineralization.
The effects of ZOL on increasing cancellous bone structure in the current
study are in line with previous mouse research (Lloyd et al., 2008; Pozzi et al.,
2009). Compared to VEH, zoledronate has been shown to increase bone
mineral density of the cancellous-rich region of the distal femoral metaphysis in
rats (Smith & Allen, 2013) and the cancellous-rich bone mineral density of the
tibial metaphysis in ovariectomized rats (Gasser, Ingold, Venturiere, Shen, &
Green, 2008). In the current study, a ZOL dose of 45 µg/kg induced positive
increases in cancellous bone and tissue mineral density compared to VEH and,
to a limited degree, increases in cortical architecture. Taken together, the
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structural data corroborate the mechanical effect of ZOL on increasing stiffness,
ultimate force, and yield force. There were thicker, more condensed and
mineralized cancellous struts that contributed to the increased elasticity, along
with the slight, but significant, impact of ZOL on cortical bone.
In terms of plasticity properties, the effect of ZOL is worth close
consideration. This study examined the effect of ZOL 3 weeks postinjection.
Compared to VEH, ZOL did not have any effect on postyield displacement or
postyield strain, both indicators of toughness (Table 4). In contrast, postyield
energy and total energy increased due to ZOL, with its simultaneous effect of
increased ultimate force and yield force appearing to be the driver for more area
under the curve (Figure 10). The contrast of whole bone and tissue level results
is interesting and suggests that on the tissue level, ZOL did not have an effect on
the organic matrix, but did influence bone geometry and mineral on the whole
bone level. Examining the tibia, Stadelmann, Bonnet, and Pioletti (2011)
conducted a study in 17 week old C57BL/6 male mice, with a single dose of ZOL
(100 µg/kg). Compared to age-matched VEH animals, ZOL produced significant
increases in stiffness, ultimate force, and postyield energy of 31%, 24%, and
60%, respectively, 11 days after administration. Although the dose of ZOL was
high, the direction of these results is in agreement with the current study, with
ZOL conferring mechanical elastic effects in a mouse of similar age, genetics,
and gender.
In a study using a dose of 100 µg/kg in adult rats, Smith and Allen (2013)
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found that 5 weeks postinjection, ZOL had no significant effect on postyield
energy, total energy, or other measures of bone plasticity, consistent with the
results of the current study. Interestingly, the authors did find that the rate of
application of force during the 3-pt bending test altered results of toughness.
Compared to VEH, ZOL only reduced plasticity and toughness measurements
when the test was conducted at the slower rate of loading (0.03 mm/s) compared
to the faster rate of loading (0.3 mm/s). Their results support the rate of force
application selected for the current study, which was a relatively similar slower
rate (0.01 mm/s). Further work should be conducted to investigate the
contribution of the rate of force application in tests with plasticity outcomes.
Differences in the dose of ZOL dose (100 µg/kg vs 45 µg/kg in the current study)
and drug latency periods (5 weeks vs 3 weeks in the current study) may
contribute to the finding of no decrease in bone toughness in the current study.
Other drug studies have examined energy absorption and toughness.
Using ibandronate or risendronate, Shahnazari et al. (2010) found that monthly
injections of these bisphosphonates for 4 months resulted in no significant
change of fracture toughness in aged and ovariectomized (shamovariectomized, ± bisphosphonate), control rats, consistent with the current
study’s results. It should be noted that femoral toughness was measured from
nano-indentation tests, rather than the 3-pt bend used in the current study. While
using a different drug type and ovariectomized rats, Shahnazari et al. (2010) did
present evidence that longer-term bisphosphonate treatment in adult rats
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resulted in no alterations of femoral fracture toughness.
Other studies using the 3-pt bending method have found effects of
bisphosphonate treatment on the plasticity of rodent bone. Gasser et al. (2008)
performed a ZOL study lasting 8 months, using ovariectomized rats that had a
starting age of 7 months. The authors presented evidence that toughness, in
terms of total energy, was only increased by ZOL at considerably higher doses
(100 and 500 µg/kg). These results are in agreement with the current study’s
finding that ZOL did not increase ductility, measured by postyield displacement.
Additionally, the authors found significant bone stiffness increases compared to
ovariectomized rats. The Gasser et al. (2008) study is a noteworthy comparison,
suggesting that the behavior of bone plasticity and toughness may be temporally
dependent, with an additional key factor being tissue age. In contrast to the
concept of Currey (2012), these data from Gasser et al. (2008) suggest that a
substantial increase in stiffness does not necessarily equate to reductions in
toughness.
After 10 months of twice weekly administrations of alendronate (28 µg/kg)
in ovariectomized rats, Ma and colleagues (2003) reported through 3-pt bending
that toughness, in terms of total energy, was significantly higher compared to
baseline and sham controls. These results are consistent with the current study,
and opposite to the concept described by Currey (2012). Drawing meaningful
comparisons with the Ma et al. (2003) study is limited due to differences such as
bisphosphonate type, dosage, duration of treatment, measurement technique,
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and animal model. Luo and Allen (2013) found reduced rib toughness and a
normal rate of remodeling in mature, female dogs after 9 months of biweekly ZOL
injections (60 µg/kg). With an increase in stiffness and a decrease in postyield
displacement, their work is in agreement with the concept proposed by Currey
(2012). The animals were not in a state of imposed bone loss, such as simulated
weightlessness or postmenopausal. The older age of the animals (1 to 2 years
of age) is worthy to note, with cortical bone naturally having a greater mean
tissue age because of its slower turnover rate. A slower turnover in cortical bone
would result in less new, less mineralized, and more ductile bone. It seems
warranted to consider that the lifespan of bone toughness may undulate
according to bone selection, subject age, and treatment. While the Luo & Allen
(2013) study is noteworthy since zoledronate and toughness were investigated,
important limitations to consider are that the bone mechanically tested was not
weight-bearing, and the frequency of ZOL injections far exceeded normal clinical
dosages.
Combined Treatment Effects
The combined treatment results of the current study showed that the ZOLtreated mice experiencing simulated weightlessness increased femoral stiffness,
preventing the deleterious effects of HU. The HU mice treated with ZOL did not
concurrently present with diminished plasticity, rejecting the principal hypothesis
of this study. Interestingly, for postyield displacement, the combined treatment
effects were additive, with ZOL not modulating the HU effect. Zoledronate
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conferred benefits to the bone, allowing greater forces to be incurred prior to a
yielding of the bone and permanent deformation. The combined treatment
conclusions for mechanical properties are shown in Figure 11.
In terms of structure, the combined treatment results showed that the
ZOL-treated mice experiencing simulated weightlessness increased their cortical
thickness, preventing HU losses. In the combined treatment of ZOL+HU,
cancellous bone volume fraction trended highly (interaction, p = 0.17), as did
trabecular number (interaction, p = 0.07), with the raw data showing a substantial
difference in the ZOL-treated animals. These data suggest that ZOL was able to
maintain cortical thickness during 3 weeks of HU, and subtly confer a trending
protective effect for cancellous parameters. These structural data help
substantiate the increase of stiffness in the mechanical properties.
Limitations
One limitation of this study is the need for a larger sample size to increase
statistical power, especially for cancellous HU losses. Another limitation is the 3
week duration for ZOL to act upon the bones of the mice. Longer term ZOL
treatment studies should be conducted to understand its effect on mechanical
properties in the context of astronauts performing 2-3 year missions to Mars.
Additionally, future studies should investigate the effectiveness of ZOL in
countering bone loss and bone quality decrements. The dog rib has been
examined during long duration bisphosphonate treatment (alendronate,
risedronate) and has shown consistent reductions in bone toughness over 1 to 3
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years (Allen & Burr, 2011; Allen, Reinwald, & Burr, 2008; Mashiba et al., 2000).
These studies show that bisphosphonates reduce the amount of energy the bone
can absorb before fracturing, but not in subjects experiencing bone losses from
unloading or estrogen deficiency. In order to draw conclusions for the structural
and mechanical health of bone in astronauts, such study designs and treatments
should be considered. For human subjects, bed rest disuse studies have also
been an analog to mimic spaceflight effects on bone and should be considered to
understand the efficacy of countermeasures such as ZOL (LeBlanc, Spector,
Evans, & Sibonga, 2007).
Notwithstanding, several studies are worthy of scientific comparison
because they show that the effect of a bisphosphonate in reducing toughness
has a temporal dependence and often only presents after longer duration
treatments. Compelling work by Burr, Liu, and Allen (2015) provided evidence
that during the first year of alendronate treatment (0.2 mg/kg, once a day) there
was, in fact, a trending increase in bone toughness. Beyond 1 year, the authors
found reduced bone toughness until the end of the 3-year study. Future studies
should examine the effect of long duration ZOL treatment on mechanical
properties of bone.
In human subjects, researchers found that 3 years after a single
intravenous dose of ZOL, biomarkers of bone remodeling remained significantly
suppressed compared to baseline (Grey et al., 2010). Along with other
bisphosphonates, ZOL is under consideration for use by astronauts during long-

58

term spaceflight missions. Future space travel has the prospect of lasting 3
years or more. With this is mind, LeBlanc and colleagues (2013) investigated the
efficacy of alendronate and exercise in mitigating bone loss in astronauts after an
average 5.5 months of spaceflight aboard the ISS. With exercise in space being
an essential routine, all subjects taking the antiresorptive treatment exercised as
well. The combined treatment of alendronate and exercise was effective in
counteracting predictable declines in bone physiological parameters associated
with spaceflight.
The amount of time ZOL has to act on bone is worth consideration, as is
the age of the subject. Ng and collaborators (2015) presented a compelling
model to investigate the condition of adynamic bone. This condition is relatively
common in chronic kidney disease, a condition where both bone formation and
bone resorption are reduced, leading to thin osteoids, decreased osteoblasts and
osteoclasts, and reductions in bone toughness. This condition has also been
suspected to result from long duration antiresorptive treatments, such as
bisphosphonates. The authors found that reductions in bone toughness were
more severe in older mice (16 months old) who were induced into presenting with
this adynamic condition compared to younger mice (4 months old). The
investigators also made an interesting point that while bone toughness in the
older mice was severely degraded compared to young, their bone mineral
density and structural data were normal. This indicates that the other bony
constituents, not measured with µCT, contributed to the reductions of toughness,
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namely bone collagen and associated organic components.
Additionally, comparing 4 month old and 16 month old controls, Ng et al.
(2015) found reductions in toughness and postyield displacement only in the
axially compressed vertebrae (L3, L4), and not in the 3-pt bending femur
mechanical results. With mouse vertebrae containing a substantial percentage
of cancellous tissue, this suggests the preferential role of cancellous tissue in
toughness changes, which was not captured in their femoral 3-pt bending tests.
Moreover, comparing the 4 month old and 16 month old controls, substantial
reductions in mineral apposition rates showed that osteoblasts were less active
in older mice, and consequently responsible for the decrease of cancellous bone
and toughness. This provides strong cellular evidence that aged tissue in the
cancellous compartment of the mouse vertebrae is disproportionately
underpinning toughness changes. In future studies, the selection of bone and
the age of the subject are important variables to consider when examining effects
on bone toughness.
The current study found that HU resulted in statistically significant
decreases in bodyweight of the mice compared to NA controls (-10%, p =
0.0001). Amblard et al. (2003) found that after 2 weeks of tail suspension,
C57BL/6 male 4 month old mice weighed significantly less than ambulatory
controls. Lloyd, Loiselle, Zhang, and Donahue (2014) found that after 3 weeks of
HU of both wild-type mice and connexin 43-deficient knockout mice (male, 6
months old), bodyweight losses were significant at -5% and -3%, respectively,
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compared to their genetic controls. This is in contrast to Alwood et al. (2010)
who reported no significant differences in body mass after 2 weeks of HU of 4
month old C57BL/6 male mice. Earlier research on the effect of HU on
bodyweight and stress biomarkers primarily used the rat model (Halloran, Bikle,
Cone, & Morey-Holton, 1988; Morey-Holton & Globus, 2002). Results from the
current study and contrasting evidence in the literature points to the need for
close monitoring of bodyweight and possible use of ANCOVA for statistical
analysis.
Bone Stiffness and Plasticity
A central limitation in this study was no direct measurement of collagen.
Bone is a composite material of both inorganic and organic components.
Collagen is critical, in that the organic matrix plays an integral role in the
toughness of bone and its plasticity. Mineral is disproportionately responsible for
stiffness and strength (ultimate force), but the behavior of bone once yield and
permanent deformation occur is largely due to collagen (Allen & Burr, 2007; Burr,
2002; Wang, Shen, Li, & Agrawal, 2002). As permanent deformation occurs at
yield, the bone will no longer be able to return to its original shape. It is primarily
the collagen and the organic matrix still withstanding the load, playing a crucial
role in the resulting ductility or brittleness. Brittleness can be defined as the
lessening of the postyield or plastic region. This brittleness manifests both in
terms of postyield displacement as well as the magnitude of strain, or point of
displacement upon the yielding of the bone (Burr, 2002). This study likely altered

61

the mineral-to-matrix ratio in the cancellous bone with ZOL, along with the
treatments (HU, ZOL) influencing measurements of geometry and amount of
bone. The mechanical 3-pt bending test resulted in a fracture of the entire bone,
enabling measurements of postyield displacement and forces, stresses, and
strains within that region. Conclusions were drawn based on the contrasting
results between the whole bone and tissue level measurements. However,
without a direct collagen measurement, a critical component for a comprehensive
analysis and cause of bone plasticity behavior is lacking. Conclusions regarding
whether HU or ZOL impacted collagen cross-linking or the stability of helical
collagen fibrils cannot be drawn (Viguet-Carrin et al., 2006).
To elucidate the role of other bone compartments in mechanical and
material properties, other techniques may be employed. Such methods include
procedures to reveal cellularity, and dynamic indices to examine bone
remodeling rates and bone microdamage. Fluorescence measurement
techniques can measure collagen with its crosslinks, and vibrational
spectroscopy techniques, which excite chemical bonds in minerals and proteins,
are being further developed to measure microscale and nanoscale outcomes
(Donnelly, 2011).
Based upon mineral being stiffer than bone collagen, Currey (2012)
suggested there is trade off, so that if a bone becomes very stiff, there will be a
corresponding reduction in toughness. This concept doesn’t consider several
important factors that contribute to bone mechanical properties. Based upon
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data from this study and the literature review, it appears that bone undergoes
undulating lifespan changes in mechanical properties corresponding with
osteoblast and osteoclast changes that impact the bone collagen matrix, mineral,
and structure (Burr et al., 2015; Kuroshima et al. 2012; Ng et al., 2015).
Additionally, the lifespan changes seem to be site-specific, depending on the
composition of the bony compartment. These age-related cellular and sitespecific changes should be considered in the Currey thesis, as they may have a
significant impact on bone remodeling quality (stiffness vs. toughness) by
inhibiting efforts to repair bone microdamage, resulting in greater fracture risk.
Further Work and Conclusions
Further research is warranted to assess the risks to skeletal health in long
term space travel. The basic science precedes the translational science, with the
hope that work with animals and ground analogs will help to inform decisions for
astronaut health regimens. Future studies should consider a model that
specifically modulates toughness, in conjunction with mitigation regimens to
elucidate not only the elastic, but also the plasticity behavior of bone in
microgravity. Additional research should also examine possible risks to skeletal
health when long-term resistance training, antiresorptive drugs, and microgravity
are combined. Chronic suppression of normal bone remodeling, paired with
aged bone that is undergoing repeated loading of the skeleton with exercise, may
lead to accumulated, unrepaired microdamage and, perhaps, stress fractures.
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Although collagen was not directly measured, certain conclusions are
merited due to the measurement of plasticity, stiffness, and geometry.
Zoledronate maintained bone structure and increased stiffness during simulated
weightlessness, while not reducing postyield displacement. Zoledronate was
effective in preventing bone losses of structure and stiffness, similar to what
astronauts might lose from microgravity. At the same time, brittleness did not
occur. Further studies are warranted, but based upon the current data, use of
zoledronate as a countermeasure to bone loss could help safeguard astronaut
skeletal health during future space missions.

64

References
Akhter, M. P., Iwaniec, U. T., Covey, M. A., Cullen, D. M., Kimmel, D. B., &
Recker, R. R. (2000). Genetic variations in bone density,
histomorphometry, and strength in mice. Calcified Tissue International, 67,
337-344. doi:10.1007/s002230001144
Akhter, M. P., Fan, Z., & Rho, J. Y. (2004). Bone intrinsic material properties in
three inbred mouse strains. Calcified Tissue International, 75, 416-420.
doi:10.1007/s00223-004-0241-7
Allen, M. R., & Burr, D. B. (2007). Mineralization, microdamage, and matrix: How
bisphosphonates influence material properties of bone. BoneKEyOsteovision, 4, 49-60. doi:10.1138/20060248
Allen, M. R., & Burr, D. B. (2011). Bisphosphonate effects on bone turnover,
microdamage, and mechanical properties: What we think we know and
what we know that we don't know. Bone, 49, 56-65. doi:10.1016/
j.bone.2010.10.159
Allen, M. R., Reinwald, S., & Burr, D. B. (2008). Alendronate reduces bone
toughness of ribs without significantly increasing microdamage
accumulation in dogs following 3 years of daily treatment. Calcified Tissue
International, 82, 354-360. doi:10.1007/s00223-008-9131-8
Alwood, J. S., Yumoto, K., Mojarrab, R., Limoli, C. L., Almeida, E. A. C., Searby,
N. D., & Globus, R. K. (2010). Heavy ion irradiation and unloading effects
on mouse lumbar vertebral microarchitecture, mechanical properties and
tissue stresses. Bone, 47, 248-255. doi:10.1016/j.bone.2010.05.004
Amblard, D., Lafage-Proust, M. H., Laib, A., Thomas, T., Rüegsegger, P.,
Alexandre, C., & Vico, L. (2003). Tail suspension induces bone loss in
skeletally mature mice in the C57BL/6J strain but not in the C3H/HeJ
strain. Journal of Bone and Mineral Research, 18, 561-569.
doi:10.1359/jbmr.2003.18.3.561
Amin, D., Cornell, S. A., Gustafson, S. K., Needle, S. J., Ullrich, J. W., Bilder, G.
E., & Perrone, M. H. (1992). Bisphosphonates used for the treatment of
bone disorders inhibit squalene synthase and cholesterol biosynthesis.
Journal of Lipid Research, 33, 1657-1663. Retrieved from
http://www.jlr.org/content/33/11/1657.short

65

Beaupre, G. S., Orr, T. E., & Carter, D. R. (1990). An approach for timedependent bone modeling and remodeling--theoretical development.
Journal of Orthopedic Research, 8, 651-661. doi:10.1002/jor.1100080506
Blaber, E. A., Dvorochkin, N., Torres, M. L., Yousuf, R., Burns., B. P., Globus, R.
K., & Almeida, E. A. C. (2014). Mechanical unloading of bone in
microgravity reduces mesenchymal and hematopoietic stem cell-mediated
tissue regeneration. Stem Cell Research, 13, 181-201. doi:10.1016/
j.scr.2014.05.005
Boivin, G. Y., Chavassieux, P. M., Santora, A. C., Yates, J., & Meunier, P. J.
(2000). Alendronate increases bone strength by increasing the mean
degree of mineralization of bone tissue in osteoporotic women. Bone, 27,
687-694. doi:10.1016/S8756-3282(00)00376-8
Bonadio, J., Jepsen, K. J., Mansoura, M. K., Jaenisch, R., Kuhn, J. L., &
Goldstein, S. A. (1993). A murine skeletal adaptation that significantly
increases cortical bone mechanical properties. Implications for human
skeletal fragility. Journal of Clinical Investigation, 92, 1697-1705.
doi:10.1172/JCI116756
Bonewald, L. F. (2011). The amazing osteocyte. Journal of Bone and Mineral
Research, 26, 229-238. doi:10.1002/jbmr.320
Bouxsein, M. L., Boyd, S. K., Christiansen, B. A., Guldberg, R. E., Jepsen, K. J.,
& Müller, R. (2010). Guidelines for assessment of bone microstructure in
rodents using micro-computed tomography. Journal of Bone and Mineral
Research, 25, 1468-1486. doi:10.1002/jbmr.141
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003). Osteoclast differentiation
and activation. Nature, 423(6937), 337-342. doi:10.1038/nature01658
Brodt, M. D., Ellis, C. B., & Silva, M. J. (1999). Growing C57Bl/6 mice increase
whole bone mechanical properties by increasing geometric and material
properties. Journal of Bone and Mineral Research, 14, 2159-2166.
doi:10.1359/jbmr.1999.14.12.2159
Burr, D. B. (2002). The contribution of the organic matrix to bone’s material
properties. Bone, 31, 8-11. doi:10.1016/S8756-3282(02)00815-3
Burr, D. B., Miller, L., Grynpas, M., Li, J., Boyde, A., Mashiba, T., … Johnston, C.
C. (2003). Tissue mineralization is increased following 1-year treatment
with high doses of bisphosphonates in dogs. Bone, 33, 960-969.
doi:10.1016/j.bone.2003.08.004
66

Burr, D. B., Liu, Z., & Allen, M. R. (2015). Duration-dependent effects of clinically
relevant oral alendronate doses on cortical bone toughness in beagle
dogs. Bone, 71, 58-62. doi:10.1016/j.bone.2014.10.010
Calliot-Augusseau, A., Lafage-Proust, M., Soler, C., Pernod, J., Dubois, F., &
Alexandre, C. (1998). Bone formation and resorption biological markers in
cosmonauts during and after a 180-day space flight (Euromir 95). Clinical
Chemistry, 44, 578-585. Retrieved from http://www.clinchem.org/content/
44/3/578.full
Chambers, T. J., & Magnus, C. J. (1982). Calcitonin alters behaviour of isolated
osteoclasts. The Journal of Pathology, 136, 27-39. doi:10.1002/path.
1711360104
Collet, P., Uebelhart, D., Vico, L., Moro, L., Hartmann, D., Roth, M., & Alexandre,
C. (1997). Effects of 1- and 6-month spaceflight on bone mass and
biochemistry in two humans. Bone, 20, 547-551. doi:10.1016/S87563282(97)00052-5
Coxon, F. P., & Taylor, A. (2008). Vesicular trafficking in osteoclasts. Seminars in
Cell & Developmental Biology, 19, 424-433. doi:10.1016/j.semcdb.
2008.08.004
Coxon, F. P., Thompson, K., & Rogers, M. J. (2006). Recent advances in
understanding the mechanism of action of bisphosphonates. Current
Opinions in Pharmacology, 6, 307-312. doi:10.1016/j.coph.2006.03.005
Crockett, J. C., Rogers, M. J., Coxon, F. P., Hocking, L. J., & Helfrich, M. H.
(2011). Bone remodelling at a glance. Journal of Cell Science, 124, 991998. doi:10.1242/jcs.063032
Currey, J. (2012). The structure and mechanics of bone. Journal of Material
Science, 47, 41-54. doi:10.1007/s10853-011-5914-9
Currey, J. D., Brear, K., & Zioupos, P. (1996). The effects of ageing and changes
in mineral content in degrading the toughness of human femora. Journal
of Biomechanics, 29, 257-260. doi:10.1016/0021-9290(95)00048-8
Doblaré, M., GarcÍa, J. M., & Gómez, M. J. (2004). Modelling bone tissue fracture
and healing: A review. Engineering Fracture Mechanics, 71, 1809-1840.
doi:10.1016/j.engfracmech.2003.08.003

67

Donnelly, E. (2011). Methods for assessing bone quality: A review. Clinical
Orthopaedics and Related Research, 469, 2128-2138. doi:10.1007/
s11999-010-1702-0
Dunford, J. E., Thompson, K., Coxon, F. P., Luckman, S. P., Hahn, F. M.,
Poulter, C. D., ... Rogers, M. J. (2001). Structure-activity relationships for
inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone
resorption in vivo by nitrogen-containing bisphosphonates. Journal of
Pharmacology and Experimental Therapeutics, 296, 235-242. Retrieved
from http://jpet.aspetjournals.org/content/296/2/235.short
Ebetino, F. H., Hogan, A. M. L., Sun, S., Tsoumpra, M. K., Duan, X., Triffitt, J. T.,
… Russell, R. G. G. (2011). The relationship between the chemistry and
biological activity of the bisphosphonates. Bone, 49, 20-33. doi:10.1016/
j.bone.2011.03.774
Ferguson, V. L., Ayers, R. A., Bateman, T. A., & Simske, S. J. (2003). Bone
development and age-related bone loss in male C57BL/6J mice. Bone, 33,
387-398. doi:10.1016/S8756-3282(03)00199-6
Ferretti, J. L., Capozza, R. F., Mondelo, N., & Zanchetta, J. R. (1993).
Interrelationships between densitometric, geometric, and mechanical
properties of rat femora: Inferences concerning mechanical regulation of
bone modeling. Journal of Bone and Mineral Research, 8, 1389-1396.
doi:10.1002/jbmr.5650081113
Flurkey, K., Currer, J. M., & Harrison, D. E. (2007). Mouse models in aging
research. In: J. G. Fox et al. (Eds.), The mouse in biomedical research
(2nd ed., Vol. 3, pp. 637–672). Burlington, MA: Elsevier Academic Press.
Retrieved from http://mouseion.jax.org/stfb2000_2009/1685
Franz-Odendaal, T. A., Hall, B. K., & Witten, P. E. (2006). Buried alive: How
osteoblasts become osteocytes. Developmental Dynamics, 235, 176-190.
doi:10.1002/dvdy.20603
Fratzl, P., & Weinkamer, R. (2007). Nature’s hierarchical materials. Progress in
Materials Science, 52, 1263-1334. doi:10.1016/j.pmatsci.2007.06.001
Frost, H. M. (2003). Bone's mechanostat: A 2003 update. The Anatomical
Record Part A: Discoveries in Molecular, Cellular, and Evolutionary
Biology, 275, 1081-1101. doi:10.1002/ar.a.10119

68

Fyhrie, D. P., & Christiansen, B. A. (2015). Bone material properties and skeletal
fragility. Calcified Tissue International, 97, 213-228. doi:10.1007/s00223015-9997-1
Gasser, J. A., Ingold, P., Venturiere, A., Shen, V., & Green, J. R. (2008). Longterm protective effects of zoledronic acid on cancellous and cortical bone
in the ovariectomized rat. Journal of Bone and Mineral Research, 23, 544551. doi:10.1359/JBMR.071207
Gere, J. M., & Timoshenko, S. (1984). Mechanics of materials. Boston: PWSKent.
Globus, R. K., & Morey-Holton, E. (2016). Hindlimb unloading: Rodent analog for
microgravity. Journal of Applied Physiology, 120, 1196-1206. doi:10.1152/
japplphysiol.00997.2015
Granke, M., Does, M. D., & Nyman, J. S. (2015). The role of water compartments
in the material properties of cortical bone. Calcified Tissue International,
97, 292-307. doi:10.1007/s00223-015-9977-5
Grey, A., Bolland, M., Wattie, D., Horne, A., Gamble, G., & Reid, I. R. (2010).
Prolonged antiresorptive activity of zoledronate: A randomized, controlled
trial. Journal of Bone and Mineral Research, 25, 2251-2255. doi:10.1002/
jbmr.103
Halloran, B. P., Bikle, D. D., Cone, C. M., & Morey-Holton, E. (1988).
Glucocorticoids and inhibition of bone formation induced by skeletal
unloading. American Journal of Physiology-Endocrinology and
Metabolism, 255, E875-E879. Retrieved from http://ajpendo.physiology.
org/content/255/6/E875
Halloran, B. P., Ferguson, V. L., Simske, S. J., Burghardt, A., Venton, L. L., &
Majumdar, S. (2002). Changes in bone structure and mass with advancing
age in the male C57BL/6J mouse. Journal of Bone and Mineral Research,
17, 1044-1050. doi:10.1359/jbmr.2002.17.6.1044
Hamrick, M. W., McPherron, A. C., Lovejoy, C. O., & Hudson, J. (2000). Femoral
morphology and cross-sectional geometry of adult myostatin-deficient
mice. Bone, 27, 343-349. doi:10.1016/S8756-3282(00)00339-2
Heer, M. A., Baecker, N., Mika, C., Boese, A., & Gerzer, R. (2005).
Immobilization induces a very rapid increase in osteoclast activity. Acta
Astronautica, 57, 31-36. doi:10.1016/j.actaastro.2004.12.007

69

Iwaniec, U. T., Wronski, T. J., Amblard, D., Nishimura, Y., van der Meulen, M. C.
H., Wade, C. E., ... Globus, R. K. (2005). Effects of disrupted β1-integrin
function on the skeletal response to short-term hindlimb unloading in mice.
Journal of Applied Physiology, 98, 690-696. doi:10.1152/japplphysiol.
00689.2004
Iwata, K., Mashiba, T., Hitora, T., Yamagami, Y., & Yamamoto, T. (2014). A large
amount of microdamages in the cortical bone around fracture site in a
patient of atypical femoral fracture after long-term bisphosphonate
therapy. Bone, 64, 183-186. doi:10.1016/j.bone.2014.04.012
Jämsä, T., Jalovaara, P., Peng, Z., Väänänen, H. K., & Tuukkanen, J. (1998).
Comparison of three-point bending test and peripheral quantitative
computed tomography analysis in the evaluation of the strength of mouse
femur and tibia. Bone, 23, 155-161. doi:10.1016/S8756-3282(98)00076-3
Jepsen, K. J., Pennington, D. E., Lee, Y. L., Warman, M., & Nadeau, J. (2001).
Bone brittleness varies with genetic background in A/J and C57BL/6J
inbred mice. Journal of Bone and Mineral Research, 16, 1854-1862.
doi:10.1359/jbmr.2001.16.10.1854
Jepsen, K. J., Silva, M. J., Vashishth, D., Guo, X. E., & van der Meulen, M. C. H.
(2015). Establishing biomechanical mechanisms in mouse models:
Practical guidelines for systematically evaluating phenotypic changes in
the diaphyses of long bones. Journal of Bone and Mineral Research, 30,
951-966. doi:10.1002/jbmr.2539
Jing, D., Cai, J., Wu, Y., Shen, G., Li, F., Xu, Q., ... Wu, X. (2014). Pulsed
electromagnetic fields partially preserve bone mass, microarchitecture,
and strength by promoting bone formation in hindlimb-suspended rats.
Journal of Bone and Mineral Research, 29, 2250-2261. doi:10.1002/
jbmr.2260
Judex, S., Garman, R., Squire, M., Busa, B., Donahue, L. R., & Rubin, C. (2004).
Genetically linked site specificity of disuse osteoporosis. Journal of Bone
and Mineral Research, 19, 607-613. doi:10.1359/JBMR.040110
Kavanagh, K. L., Guo, K., Dunford, J. E., Wu, X., Knapp, S., Ebetino, F. H., …
Oppermann, U. (2006). The molecular mechanism of nitrogen-containing
bisphosphonates as antiosteoporosis drugs. Proceedings of the National
Academy of Sciences, 103, 7829-7834. doi:10.1073/pnas.0601643103

70

Ke, H. Z., Shen, V. W., Qi, H., Crawford, D. T., Wu, D. D., Liang, X. G., …
Thompson, D. D. (1998). Prostaglandin E2 increases bone strength in
intact rats and in ovariectomized rats with established osteopenia. Bone,
23, 249-255. doi:10.1016/S8756-3282(98)00102-1
Kerschnitzki, M., Wagermaier, W., Roschger, P., Seto, J., Shahar, R., Duda, G.
N., … Fratzl, P. (2011). The organization of the osteocyte network mirrors
the extracellular matrix orientation in bone. Journal of Structural
Biology, 173, 303-311. doi:10.1016/j.jsb.2010.11.014
Keyak, J. H., Koyama, A., K., LeBlanc, A., Lu, Y., & Lang, T. F. (2009).
Reduction in proximal femoral strength due to long-duration spaceflight.
Bone, 44, 449-453. doi:10.1016/j.bone.2008.11.014
Khajuria, D. K., Razdan, R., & Mahapatra, D. R. (2015). Effect of combined
treatment with zoledronic acid and propranolol on mechanical strength in
an rat model of disuse osteoporosis. Revista Brasileira de Reumatologia
(English Edition), 55, 501-511. doi:10.1016/j.rbre.2014.07.007
Kodama, Y., Umemura, Y., Nagasawa, S., Beamer, W. G., Donahue, L. R.,
Rosen, C. R., … Farley, J. R. (2000). Exercise and mechanical loading
increase periosteal bone formation and whole bone strength in C57BL/6J
mice but not in C3H/Hej mice. Calcified Tissue International, 66, 298-306.
doi:10.1007/s002230010060
Kuroshima, S., Go, V. A. A., & Yamashita, J. (2012). Increased numbers of
nonattached osteoclasts after long-term zoledronic acid therapy in mice.
Endocrinology, 153, 17-28. doi:10.1210/en.2011-1439
Lakkakorpi, P. T., & Väänänen, H. K. (1996). Cytoskeletal changes in osteoclasts
during the resorption cycle. Microscopy Research and Technique, 33,
171-181. doi:10.1002/(SICI)1097-0029(19960201)33:2<171::AIDJEMT7>3.0.CO;2-W
Lang, T., LeBlanc, A., Evans, H., Lu, Y., Genant, H., & Yu, A. (2004). Cortical
and trabecular bone mineral loss from the spine and hip in long-duration
spaceflight. Journal of Bone and Mineral Research, 19, 1006-1012.
doi:10.1359/JBMR.040307
LeBlanc, A., Lin, C., Shackelford, L., Sinitsyn, V., Evans, H., Belichenko, O., …
Feeback, D. (2000). Muscle volume, MRI relaxation times (T2), and body
composition after spaceflight. Journal of Applied Physiology, 89, 21582164. Retrieved from http://jap.physiology.org/content/89/6/2158.short

71

LeBlanc, A., Matsumoto, T., Jones, J., Shapiro, J., Lang, T., Shackelford, L., …
Ohshima, H. (2013). Bisphosphonates as a supplement to exercise to
protect bone during long-duration spaceflight. Osteoporosis International,
24, 2105-2114. doi:10.1007/s00198-012-2243-z
LeBlanc, A. D., Spector, E. R., Evans, H. J., & Sibonga, J. D. (2007). Skeletal
responses to space flight and the bed rest analog: A review. Journal of
Musculoskeletal and Neuronal Interactions, 7, 33-47. Retrieved from
http://www.ismni.org/jmni/pdf/27/07LEBLANC.pdf
Lloyd, S. A., Loiselle, A. E., Zhang, Y., & Donahue, H. J. (2014). Evidence for the
role of connexin 43-mediated intercellular communication in the process of
intracortical bone resorption via osteocytic osteolysis. BMC
Musculoskeletal Disorders, 15, 1-8. doi:10.1186/1471-2474-15-122
Lloyd, S. A., Travis, N. D., Lu, T., & Bateman, T. A. (2008). Development of a
low-dose anti-resorptive drug regimen reveals synergistic suppression of
bone formation when coupled with disuse. Journal of Applied Physiology,
104, 729-738. doi:10.1152/japplphysiol.00632.2007
Loehr, J. A., Lee, S. M. C., English, K. L., Sibonga, J., Smith, S. M., Spiering, B.
A., & Hagan, R. D. (2010). Musculoskeletal adaptations to training with the
advanced resistive exercise device. Medicine & Science in Sports &
Exercise, 43, 146-156. doi:10.1249/MSS.0b013e3181e4f161
Luo, T. D., & Allen, M. R. (2013). Short-courses of dexamethasone abolish
bisphosphonate-induced reductions in bone toughness. Bone, 56, 199203. doi.org/10.1016/j.bone.2013.06.004
Luxenburg, C., Geblinger, D., Klein, E., Anderson, K., Hanein, D., Geiger, B., &
Addadi, L. (2007). The architecture of the adhesive apparatus of cultured
osteoclasts: From podosome formation to sealing zone assembly. PLoS
ONE, 2, e179. doi:10.1371/journal.pone.0000179
Luxenburg, C., Parsons, J. T., Addadi, L., & Geiger, B. (2006). Involvement of the
Src-cortactin pathway in podosome formation and turnover during
polarization of cultured osteoclasts. Journal of Cell Science, 119, 48784888. doi:10.1242/jcs.03271
Ma, Y. L., Bryant, H. U., Zeng, Q., Schmidt, A., Hoover, J., Cole, H. W., ... Sato,
M. (2003). New bone formation with teriparatide [human parathyroid
hormone-(1–34)] is not retarded by long-term pretreatment with
alendronate, estrogen, or raloxifene in ovariectomized rats. Endocrinology,
144, 2008-2015. doi:10.1210/en.2002-221061
72

Manolagas, S. C. (2000). Birth and death of bone cells: Basic regulatory
mechanisms and implications for the pathogenesis and treatment of
osteoporosis 1. Endocrine Reviews, 21, 115-137. doi:10.1210/
edrv.21.2.0395
Mashiba, T., Hirano, T., Turner, C. H., Forwood, M. R., Johnston, C. C., & Burr,
D. B. (2000). Suppressed bone turnover by bisphosphonates increases
microdamage accumulation and reduces some biomechanical properties
in dog rib. Journal of Bone and Mineral Research, 15, 613-620.
doi:10.1359/jbmr.2000.15.4.613
Mellis, D. J., Itzstein, C., Helfrich, M. H., & Crockett, J. C. (2011). The skeleton: A
multi-functional complex organ. The role of key signalling pathways in
osteoclast differentiation and in bone resorption. Journal of Endocrinology,
211, 131-143. doi:10.1530/JOE-11-0212
Morey-Holton, E. R., & Globus, R. K. (1998). Hindlimb unloading of growing rats:
A model for predicting skeletal changes during space flight. Bone, 22, 8388. doi:10.1016/S8756-3282(98)00019-2
Morey-Holton, E. R., & Globus, R. K. (2002). Hindlimb unloading rodent model:
Technical aspects. Journal of Applied Physiology, 92, 1367-1377.
doi:10.1152/japplphysiol.00969.2001
Nabavi, N., Khandani, A., Camirand, A., & Harrison, R. E. (2011). Effects of
microgravity on osteoclast bone resorption and osteoblast cytoskeletal
organization and adhesion. Bone, 49, 965-974. doi:10.1016/j.bone.2011
.07.036
Nancollas, G. H., Tang, R., Phipps, R. J., Henneman, Z., Gulde, S., Wu, W., …
Ebetino, F. H. (2006). Novel insights into actions of bisphosphonates on
bone: Differences in interactions with hydroxyapatite. Bone, 38, 617-627.
doi:10.1016/j.bone.2005.05.003
National Research Council (US) Committee for the Update of the Guide for the
Care and Use of Laboratory Animals (2011). Guide for the Care and Use
of Laboratory Animals [8th ed.]. Washington (DC): National Academies
Press. Retrieved from http://www.ncbi.nlm.nih.gov/books/NBK54050/ doi:
10.17226/12910
Neve, A., Corrado, A., & Cantatore, F. P. (2011). Osteoblast physiology in normal
and pathological conditions. Cell and Tissue Research, 343, 289-302.
doi:10.1007/s00441-010-1086-1

73

Ng, A. H., Omelon, S., Variola, F., Allo, B., Willett, T. L., Alman, B. A., & Grynpas,
M. D. (2015). Adynamic bone decreases bone toughness during aging by
affecting mineral and matrix. Journal of Bone and Mineral Research, 31,
369-379. doi:10.1002/jbmr.2702
Orriss, I. R., Burnstock, G., & Arnett, T. R. (2010). Purinergic signalling and bone
remodelling. Current Opinion in Pharmacology, 10, 322-330. doi:10.1016/
j.coph.2010.01.003
Orwoll, E. S., Adler, R. A., Amin, S., Binkley, N., Lewiecki, E. M., Petak, S. M., …
Sibonga, J. D., (2013). Skeletal health in long-duration astronauts: Nature,
assessment, and management recommendations from the NASA Bone
Summit. Journal of Bone and Mineral Research, 28, 1243-1255.
doi:10.1002/jbmr.1948
Ory, S., Brazier, H., Pawlak, G., & Blangy, A. (2008). Rho GTPases in
osteoclasts: Orchestrators of podosome arrangement. European Journal
of Cell Biology, 87, 469-477. doi:10.1016/j.ejcb.2008.03.002
Plotkin, L. I., Bivi, N., & Bellido, T. (2011). A bisphosphonate that does not affect
osteoclasts prevents osteoblast and osteocyte apoptosis and the loss of
bone strength induced by glucocorticoids in mice. Bone, 49, 122-127.
doi:10.1016/j.bone.2010.08.011
Pozzi, S., Vallet, S., Mukherjee, S., Cirstea, D., Vaghela, N., Santo, L., …
Schoonmaker, J. (2009). High-dose zoledronic acid impacts bone
remodeling with effects on osteoblastic lineage and bone mechanical
properties. Clinical Cancer Research, 15, 5829-5839. doi:10.1158/10780432.CCR-09-0426
Reid, I. R (2009). Osteonecrosis of the jaw — Who gets it, and why? Bone, 44, 410. doi:10.1016/j.bone.2008.09.012
Reid, I. R., Brown, J. P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel,
U., … Meunier, P. J. (2002). Intravenous zoledronic acid in
postmenopausal women with low bone mineral density. New England
Journal of Medicine, 346, 653-661. doi:10.1056/NEJMoa011807
Rogers, M. J., Gordon, S., Benford, H. L., Coxon, F. P., Luckman, S. P.,
Monkkonen, J., & Frith, J. C. (2000). Cellular and molecular mechanisms
of action of bisphosphonates. Cancer, 88(S12), 2961-2978. doi: 10.1002/
1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L

74

Russell, R. G. G. (2011). Bisphosphonates: The first 40 years. Bone, 49, 2-19.
doi:10.1016/j.bone.2011.04.022
Schriefer, J. L., Robling, A. G., Warden, S. J., Fournier, A. J., Mason, J. J., &
Turner, C. H. (2005). A comparison of mechanical properties derived from
multiple skeletal sites in mice. Journal of Biomechanics, 38, 467-475.
doi:10.1016/j.jbiomech.2004.04.020
Shahnazari, M., Kurimoto, P., Boudignon, B. M., Orwoll, B. E., Bikle, D. D., &
Halloran, B. P. (2012). Simulated spaceflight produces a rapid and
sustained loss of osteoprogenitors and an acute but transitory rise of
osteoclast precursors in two genetic strains of mice. American Journal of
Physiology-Endocrinology and Metabolism, 303, E1354-E1362.
doi:10.1152/ajpendo.00330.2012
Shahnazari, M., Yao, W., Dai, W., Wang, B., Ionova-Martin, S. S., Ritchie, R. O.,
... Lane, N. E. (2010). Higher doses of bisphosphonates further improve
bone mass, architecture, and strength but not the tissue material
properties in aged rats. Bone, 46, 1267-1274. doi:10.1016/j.bone.
2009.11.019
Shane, E., Burr, D., Ebeling, P. R., Abrahamsen, B., Adler, R. A., Brown, T. D., ...
Dempster, D. (2010). Atypical subtrochanteric and diaphyseal femoral
fractures: Report of a task force of the American Society for Bone and
Mineral Research. Journal of Bone and Mineral Research, 25, 2267-2294.
doi:10.1002/jbmr.253
Shirazi-Fard, Y., Kupke, J. S., Bloomfield, S. A., & Hogan, H. A. (2013).
Discordant recovery of bone mass and mechanical properties during
prolonged recovery from disuse. Bone, 52, 433-443. doi:10.1016/
j.bone.2012.09.021
Silva, M. J., Brodt, M. D., Wopenka, B., Thomopoulos, S., Williams, D., Wassen,
M. H., … Bank, R. A. (2006). Decreased collagen organization and
content are associated with reduced strength of demineralized and intact
bone in the SAMP6 mouse. Journal of Bone and Mineral Research, 21,
78-88. doi:10.1359/JBMR.050909
Silverman, S., & Christiansen, C. (2012). Individualizing osteoporosis therapy.
Osteoporosis International, 23, 797-809. doi:10.1007/s00198-011-1775-y

75

Smith, E. A., Frankenburg, E. P., Goldstein, S. A., Koshizuka, K., Elstner, E.,
Said, J., … Koeffler, H. P. (2000). Effects of long-term administration of
vitamin D3 analogs to mice. Journal of Endocrinology, 165, 163-172.
doi:10.1677/joe.0.1650163
Smith, E. R., & Allen, M. R. (2013). Bisphosphonate-induced reductions in rat
femoral bone energy absorption and toughness are testing ratedependent. Journal of Orthopaedic Research, 31, 1317-1322.
doi:10.1002/jor.22343
Smith, S. M., Abrams, S. A., Davis-Street, J., Heer, M. A., O'Brien, K., Wastney,
M., & Zwart, S. (2014). Fifty years of human space travel: Implications for
bone and calcium research. Annual Review of Nutrition, 34, 377-400.
doi:10.1146/annurev-nutr-071813-105440
Smith, S. M., Heer, M. A., Shackelford, L. C., Sibonga, J. D., Ploutz-Snyder, L., &
Zwart, S. R. (2012). Benefits for bone from resistance exercise and
nutrition in long-duration spaceflight: Evidence from biochemistry and
densitometry. Journal of Bone and Mineral Research, 27, 1896-1906.
doi:10.1002/jbmr.1647
Smith, S. M., Wastney, M. E., O’Brien, K. O., Morukov, B., V., Larina, I. M.,
Abrams, S. … Shackelford, L. C. (2005). Bone markers, calcium
metabolism, and calcium kinetics during extended-duration space flight on
the Mir Space Station. Journal of Bone and Mineral Research, 20, 208218. doi:10.1359/JBMR.041105
Smith, S. M., Zwart, S. R., Block, G., Rice, B. L., & Davis-Street, J. E. (2005).
The nutritional status of astronauts is altered after long-term space flight
aboard the International Space Station. Journal of Nutrition, 135, 437-443.
Retrieved from http://jn.nutrition.org/content/135/3/437.long
Spatz, J. M., Ellman, R., Cloutier, A. M., Louis, L., van Vliet, M., Suva, L. J., …
Bouxsein, M. L. (2013). Sclerostin antibody inhibits skeletal deterioration
due to reduced mechanical loading. Journal of Bone and Mineral
Research, 28, 865-874. doi:10.1002/jbmr.1807
Stadelmann, V. A., Bonnet, N., & Pioletti, D. P. (2011). Combined effects of
zoledronate and mechanical stimulation on bone adaptation in an axially
loaded mouse tibia. Clinical Biomechanics, 26, 101-105. doi:10.1016/
j.clinbiomech.2010.08.014

76

Stenbeck, G., Lawrence, K. M., & Albert, A. P. (2012). Hormone-stimulated
modulation of endocytic trafficking in osteoclasts. Frontiers in
Endocrinology, 3(103), 1-9. doi:10.3389/fendo.2012.00103
Tamma, R., Colaianni, G., Camerino, C., Di Benedetto A., Greco G., Strippoli,
M., … Zallone, A. (2009). Microgravity during spaceflight directly affects in
vitro osteoclastogenesis and bone resorption. FASEB Journal, 23, 25492554. doi:10.1096/fj.08-127951
Turner, C. H., & Burr, D. B. (1993). Basic biomechanical measurements of bone:
A tutorial. Bone, 14, 595-608. doi:10.1016/8756-3282(93)90081-K
Turner, C. H., Hsieh, Y. F., Müller, R., Bouxsein, M. L., Baylink, D. J., Rosen, C.
J., … Beamer, W. G. (2000). Genetic regulation of cortical and trabecular
bone strength and microstructure in inbred strains of mice. Journal of
Bone and Mineral Research, 15, 1126-1131. doi:10.1359/
jbmr.2000.15.6.1126
Turner, R. T. (2000). Invited review: What do we know about the effects of
spaceflight on bone? Journal of Applied Physiology, 89, 840-847.
Retrieved from http://jap.physiology.org/content/89/2/840
van der Meulen, M. C. H., & Boskey, A. L. (2012). Atypical subtrochanteric
femoral shaft fractures: Role for mechanics and bone quality. Arthritis
Research & Therapy, 14, 1-8. doi:10.1186/ar4013
Vico, L., Collet, P., Guignandon, A., Lafage-Proust, M. H., Thomas, T., Rehailia,
M., & Alexandre, C. (2000). Effects of long-term microgravity exposure on
cancellous and cortical weight-bearing bones of cosmonauts. Lancet, 355,
1607-1611. doi:10.1016/S0140-6736(00)02217-0
Viguet-Carrin, S., Garnero, P., & Delmas, P. D. (2006). The role of collagen in
bone strength. Osteoporosis International, 17, 319-336. doi:10.1007/
s00198-005-2035-9
Voide, R., van Lenthe, G. H., & Müller, R. (2008). Bone morphometry strongly
predicts cortical bone stiffness and strength, but not toughness, in inbred
mouse models of high and low bone mass. Journal of Bone and Mineral
Research, 23, 1194-1203. doi:10.1359/JBMR.080311
Wagermaier, W., Klaushofer, K., & Fratzl, P. (2015). Fragility of bone material
controlled by internal interfaces. Calcified Tissue International, 97, 201212. doi:10.1007/s00223-015-9978-4

77

Wang, X., Shen, X., Li, X., & Agrawal, C. M. (2002). Age-related changes in the
collagen network and toughness of bone. Bone, 31, 1-7. doi:10.1016/
S8756-3282(01)00697-4
Weivoda, M. M., & Oursler, M. J. (2014). The roles of small GTPases in
osteoclast biology. Orthopedic & Muscular System: Current Research, 3,
161-168. doi:10.4172/2161-0533.1000161
Wergedal, J. E., Sheng, M. C., Ackert-Bicknell, C. L., Beamer, W. G., & Baylink,
D. J. (2002). Mouse genetic model for bone strength and size phenotypes:
NZB/B1NJ and RF/J inbred strains. Bone, 31, 670-674. doi:10.1016/
S8756-3282(02)00908-0
Wergedal, J. E., Sheng, M. H. C., Ackert-Bicknell, C. L., Beamer, W. G., &
Baylink, D. J. (2005). Genetic variation in femur extrinsic strength in 29
different inbred strains of mice is dependent on variations in femur crosssectional geometry and bone density. Bone, 36, 111-122. doi:10.1016/
j.bone.2004.09.012
Zaidi, M., Inzerillo, A. M., Moonga, B. S., Bevis, P. J. R., & Huang, C. H. (2002).
Forty years of calcitonin—where are we now? A tribute to the work of Iain
Macintyre, FRS. Bone, 30, 655-663. doi:10.1016/S8756-3282(02)00688-9
Zhang, F. L., & Casey, P. J. (1996). Protein prenylation: Molecular mechanisms
and functional consequences. Annual Review of Biochemistry, 65, 241269. doi:10.1146/annurev.bi.65.070196.001325
Zioupos, P., Currey, J. D., & Hamer, A. J. (1999). The role of collagen in the
declining mechanical properties of aging human cortical bone. Journal of
Biomedical Materials Research, 45, 108-116. doi:10.1002/(SICI)10974636(199905)45:2<108::AID-JBM5>3.0.CO;2-A

78

